Sneeze, Wheeze & Itch Associates
 
Allergy, Asthma & Immunology Research Portfolio
 

RESEARCH PORTFOLIO

 

Sneeze, Wheeze & Itch Associates, LLC

 

2010 Jacobssen Drive

Normal, IL 61761

(309) 452-0995

 
 

Allergic Rhinitis Research Experience

Alcon - Safety of PANTANASE®Nasal Spray with Perennial Allergic Rhinitis.

Alcon Research, Ltd. - Safety Study of Olopatadine Nasal Spray (Perennial Allergic Rhinitis).

Alcon Research, Ltd. - Safety and Efficacy Study of Olopatadine HCL Nasal Spray 665 mcg Versus Olopatadine HCL Nasal Spray Vehicle Versus Astelin in Treatment of Seasonal Allergic Rhinitis.

Alcon Research - Safety and Efficacy of Olopatadine Hydrochloride Nasal Spray in Pediatric Patients (Perennial Allergic Rhinitis).

Alcon Research- Safety and Efficacy Study of Olopatadine Nasal Spray 0.1% versus Olopatadine Nasal Spray Vehicle in the Prevention of Symptoms of Seasonal Allergic Rhinitis with Azelastine HCI Nasal Spray 0.1% (Astelin®) as a Reference Standard.

ALK Laboratories - A Phase III Trial Assessing the Efficacy and Safety of Grazax in Subjects with Seasonal Grass Pollen Induced Rhinoconjunctivitis with or without Asthma (Seasonal Allergic Rhinitis).

Allergenics- A Phase IIb Parallel Group, Placebo Controlled Study of Two Different Maintenance Doses of Orally Administered Microencapusulated Ragweed Pollen Extract. (Seasonal Allergic Rhinitis)

Allergy Therapeutics - Efficacy and Safety/Tolerability of Grass MATA MPL, a Randomized, Placebo-Controlled, Double-Blind Study (Seasonal Allergic Rhinitis).

Allergy Therapeutics - Efficacy and Safety/Tolerability of Ragweed MATA MPL, a Randomized, Placebo-Controlled, Double-Blind Study (Seasonal Allergic Rhinitis).

Altana Pharma - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Clinical Trial Designed to Assess the Safety and Tolerability of Ciclesonide (200 mcg Once Daily), Applied as a Nasal Spray for Twelve Weeks, in the Treatment of Perennial Allergic Rhinitis (PAR) in Pediatric Patients 2-5 Years of Age.

Altana Pharma- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Trial Designed to Assess the Efficacy and Safety of Ciclesonide Applied as a Nasal Spray at Three Dose Levels (100 mg, 200mg, or 25mg, once daily) in the Treatment of Perennial Allergic Rhinitis (PAR) in Patients 6 - 11 Years of Age

Altana Pharma - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Trial to Assess the Long Term (48 Weeks) Safety of Ciclesonide, Applied as a Nasal Spray (200 µg Once Daily) in the Treatment of Perennial Allergic Rhinitis (PAR) in Patients 12 Years and Older.

AstraZeneca- A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Phase II Study to Assess the Efficacy and Safety of RHINOCORT AQUA® (budesonide) Nasal Spray, 16 μg , 32 μg and 64 μg per Day Versus Placebo in Pediatric Subjects, Ages 2-5 Years Old with Allergic Rhinitis.

AstraZeneca- A Multi-Center, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety, and Functionality of a New Nasal Device with Reformulated Rhinocort Aqua® (budesonide) Versus the Current Product and Versus Placebo in Subjects with Seasonal Allergic Rhinitis (SAR).

AstraZeneca- A Randomized Open-Label Comparison of Rhinocort® (Budesonide) Aqua Pump Spray, versus Nasalcrom® (Cromolyn Sodium) in the Treatment of Children with Perennial Allergic Rhinitis.

Aventis Pharmaceuticals - A Multicenter Study to Assess the Safety and Pharmacokinetics of Open-Label 30 mg Single Dose Fexofenadine Hydrochloride Oral Suspension (6mg/ml) in Pediatric Subjects 2-5 Years of Age (Allergic Rhinitis).

Aventis- A Multicenter, Double-Blind, Randomized, Parallel Study Comparing the Efficacy and Safety of Fexofenadine 120 mg BID, Fexofenadine 240 mg BID, and Placebo in Subjects with Perennial Allergic Rhinitis.

Aventis- A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Study to Assess the Safety and Tolerability of Fexofenadine Hydrochloride 15mg in Children with Allergic Rhinitis.

Aventis- A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Study to Assess the Safety and Tolerability of Fexofenadine Hydrochloride 30 mg in Children with Allergic Rhinitis.

Aventis- A Multicenter, Randomized, Single-Blind, Active-Controlled, Parallel Group Study Comparing the Efficacy of Nasacort® AQ Starting Dose of 220 mcg QD with Rhinocort AquaTM Starting Dose of 64 mcg QD Given for One Week for the Treatment of Seasonal Allergic Rhinitis Symptoms in Patients 12-65 Years of Age.

Aventis- A Multicenter, Double-Blind, Randomized, Parallel Study Comparing the Efficacy and Safety of Fexofenadine 120 mg BID, Fexofenadine 240 mg QD, and Placebo in Subjects with Perennial Allergic Rhinitis.

Aventis- A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Study to Assess the Safety and Tolerability of Fexofenadine HCL 30 mg Twice a Day During Treatment of Children 2 Through 5 Years of Age with Allergic Rhinitis.

Aventis- A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study Assessing the Efficacy and Safety of Oral Fexofenadine HCI Tablets 30 mg Twice a Day in Pediatric Subjects (6 to 11 Years) in the Treatment of Seasonal Allergic Rhinitis.

Aventis - A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Four-Week Efficacy and Safety Evaluation of Nasacort® AQ 110 µg QD, Followed by Six-Month Open-Label Safety in Children Ages 2-5 Years with Perennial Allergic Rhinitis.

Boehringer Ingelheim- Randomized, Double-Blind, Parallel, Placebo-Controlled Multicenter Trial of Atrovent® Nasal Spray 0.06% (84 mcg/nostril administered QID) in Patients with Seasonal Allergic Rhinitis that are Sensitive to Ragweed Pollen Phase III.

Cobalis - A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging Study of the Safety and Efficacy of Pre-Seasonal Sublingual Cyanocobalamin Lozenges on Moderate to Moderately Severe Seasonal Allergic Rhinitis in Humans.

Curalogic - A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy and Safety of Oral Microencapsulated Ragweed Pollen Extract Administered Prior To And During the Ragweed Season.

Dynavax Technologies - A Randomized, Double-Masked, Placebo-Controlled, Multicenter, Dose-Regimen Study of the Efficacy and Safety of TOLAMBA in Ragweed-Allergic RhinitisAdults.

Dynavax - A Phase IIb, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Subcutaneously Administered Dynavax Amb a 1 Immunostimulatory Oligodeoxyribonucleotide Conjugate (AIC) in Ragweed-Allergic Adults.

Dynavax- A Phase I,Observer-blind,Randomized,Placebo-Controlled Study of the Tolerability and Immunogenicity of Subcutaneously Administered Dynavax Amb a 1 Immunostimulatory Oligodeoxyribonucleotide Conjugate (AIC) in Ragweed-Allergic Children.

Dynavax Technologies Corp.- A Phase III, Non-Pivotal, Double-Blind, Randomized Study of the Efficacy, Safety and Tolerability of Subcutaneously Administered Dynavax Amb a 1 Immunostimulatory Oligodeoxyribonucleotide Conjugate (AIC) Plus Antihistamine and Decongestant Versus Antihistamine and Decongestant Alone in Ragweed Allergic Children.

GlaxoSmithKline - A Comparison of Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine in the Treatment of Seasonal Allergic Rhinitis

GlaxoSmithKline- An Efficacy and Safety Study of Fluticasone Propionate (FP) Aqueous Nasal Spray in Subjects with Perennial Allergic Rhinitis.

Glaxo Wellcome- A Double-Blind, Double-Dummy, Randomized, Placebo-Controlled, Parallel-Group Comparison of Fluticasone Propionate Aqueous Nasal Spray and Triamcinolone Acetonide Aqueous Nasal Spray in Subjects with Seasonal Allergic Rhinitis.

Glaxo Wellcome- A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Fluticasone Propionate Aqueous Nasal Spray Versus Placebo Followed by a One Year Open-Label Safety Extension in Subjects with Perennial Nonallergic Rhinitis.

Glaxo Wellcome- A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Potential Effects of a Six-Week Course of Fluticasone Propionate Aqueous Nasal Spray (200mcg QD) on the HPA-Axis in >2 and <4 Year-Old Subjects with Allergic Rhinitis.

Glaxo Wellcome- Double-Blind, Double-Dummy, Randomized, Parallel Group Comparison of the Efficacy and Safety Outcomes of Fluticasone Propionate Aqueous Nasal Spray Versus Encapsulated Loratadine Tablets Versus Placebo for Four Weeks in Subjects with Seasonal Allergic Rhinitis.

Glaxo Wellcome- A Multi-Center, Randomized, Double-Blind, Parallel-Group Study to Assess the Potential Growth Effects of a One-Year Course of Fluticasone Propionate Aqueous Nasal Spray (200mcg QD) Versus Placebo in Pre-Pubescent, Pediatric Subjects with Perennial Allergic Rhinitis.

Glaxo Wellcome- Double-Blind, Double-Dummy, Randomized, Parallel Group Comparison of Fluticasone Propionate Aqueous Nasal Spray Versus Encapsulated Loratadine Tablets Versus a Combination of Fluticasone and Loratadine Versus Placebo for Two Weeks in Subjects with Seasonal Allergic Rhinitis.

Greer Laboratories, Inc - Parallel, Randomized, Double-Blind, Placebo-Controlled Trial in Adults for the Sublingual-Oral Immunotherapy (SLIT) of Allergic Rhinoconjunctivitis with or Without asthma Caused by Ragweed Pollen.

Hoechst Marion Roussel - A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study Assessing The Efficacy And Safety Of Oral Fexofenadine HCL Tablets 30 mg Twice A Day In Pediatric Subjects (6 To 11 Years) In The Treatment Of Seasonal Allergic Rhinitis.

Hoechst Marion Roussel, Inc.- A Double-Blind Randomized, Parallel Study Comparing the Efficacy and Safety of Fexofenadine HCI 120 mg Q.D., 180 mg Q.D., Cetrizine HCI 10 mg Q.D., and Placebo Q.D. in the Treatment of Perennial Allergic Rhinitis.

Hoechst Marion Roussel, Inc.- A Double-Blind Randomized, Parallel Study Comparing The Efficacy And Safety Of Fexofenadine HCI 120 mg Q.D., 180 mg Q.D., Cetirizine HCI 10 mg Q.D. In The Treatment Of Perennial Allergic Rhinitis.

Hoechst Marion Roussel, Inc.- A Double-Blind Randomized, Placebo-Controlled Parallel Study Comparing The Efficacy And Safety Of Fexofenadine HCL 120 mg And 180 mg QD In The Treatment Of Autumn Seasonal Allergic Rhinitis.

Hoechst Marion Roussel, Inc.- A Double-Blind Randomized, Placebo-Controlled Parallel Study Comparing The Efficacy And Safety Of Three Dosage Strengths Of Fexofenadine HCL (15, 30 And 60 mg BID) In Pediatric Patients (Ages 6 To 11 Years) In The Treatment Of Seasonal Allergic Rhinitis.

Hoffman-La Roche - A Multiple-Center, Single-Ascending Dose, Randomized, Observer-blinded, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of huMAb OX40L Following IV Administration in Individuals with Allergic Rhinitis.

Hoffman La-Roche - A Multiple-Center, Multiple-Ascending dose, Randomized, Observer-Blinded, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of huMAb OX40L following IV administration in Individuals with Allergic Rhinitis.

IDEC- A Phase II, Randomized, Blinded, Placebo-Controlled, Multiple-Dose, Dose-Finding Study to Evaluate the Safety and Clinical Activity of IDEC-152 in Patients With Ragweed-Induced Seasonal Allergic Rhinitis.

Immulogic- An Exploratory Efficacy and Safety Study of ALLERVAX® RAGWEED Peptides Using a Seasonal Model. (Seasonal Allergic Rhinitis)

ImmuLogic- An Efficacy and Safety Study of Allervax Ragweed Peptides Using a Seasonal Model. (Seasonal Allergic Rhinitis)

ImmunLogic- A Safety and Efficacy Study of Allervax Ragweed Peptides Using an In-Season Dosing Model. (Seasonal Allergic Rhinitis)

Integrated Therapeutics Group, Inc. - A Preference Evaluation of Nasonex Nasal Spray (Unscented) vs. Flonase Nasal Spray (Scented) in Subjects with Symptomatic Allergic Rhinitis (AR) Single-Dose Cross-Over.

Integrated Therapeutics Group, Inc. - A Placebo Controlled Study of the Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg in the Treatment of Subject with Symptomatic Seasonal Allergic Rhinitis (SAR).

Integrated Therapeutics- A Placebo Controlled Study of the Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg in the Treatment of Subjects with Symptomatic Seasonal Allergic Rhinitis.

Integrated Therapeutics Group- Efficacy and Safety of Desloratadine 10mg Daily Versus Placebo in Subjects with Allergic Airway Disease During the Pollen Season.

Integrated Therapeutics Group- A Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Treatment of Seasonal Allergic Rhinitis (SAR) in Subjects with Co-Morbid Asthma and a History of Seasonal Exacerbations of Asthma of Medical Resources Utilization (for Asthma and SAR).

Ista -A randomized, double-masked, placebo-controlled, parallel group, confirmatory natural exposure study of the safety and effectiveness of Bepreve (bepotastine besilate ophthalmic solution) 1.5% for the treatment of seasonal allergic conjunctivitis associated with nasal allergy symptoms.

IVAX - A Randomized, Double-Blind, Double-Dummy, Parallel Group Study to Determine the Safety and Efficacy of Loteprednol Etabonate Nasal Spray Compared to Fluticasone Propionate Nasal Spray (Flonase®) and Placebo in Patients with Ragweed-Induced Seasonal Allergic Rhinitis.

McNeil- Clinical Use Study Comparing Nasalcrom® Nasal Solution 4% to Placebo Nasal Solution in the Treatment of the Symptoms Associated with Seasonal Allergic Rhinitis.

MedPointe - Active-Controlled Trial of the Safety and Tolerability of MP03-36 in Patients with Perennial Allergic Rhinitis.

Meda - Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of MP03-36 (0.15% solution) and MP03-33 (0.10% solution) in Children Ages >6 to <12 with Perennial Allergic Rhinitis

MedPointe- Randomized,, Double-Blind Trial of MP29-02 Nasal Spray Compared to Placebo, Azelastine Hydrochloride Nasal Spray, and Fluticasone Propionate Nasal Spray in the Treatment of Patients with Seasonal Allergic Rhinitis.

MedPointe - Randomized, Double-Blind, Placebo-Controlled Trial of Safety and Efficacy of MP-03-36 and MP03-33 Compared to Placebo in Patients with Seasonal Allergic rhinitis.

MedPointe - Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of MP036-36 in Patients with Seasonal Allergic rhinitis.

MedPointe Pharmaceuticals - Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of MP03-33 in Patients with Seasonal Allergic Rhinitis.

MedPointe - Double-Blind Trial of Astelin® (azelastine hydrochloride) Nasal Spray Compared to Zyrtec® (cetirizine) Tablets in the Treatment of Patients with Seasonal Allergic Rhinitis.

MedPointe- A Randomized, Single- and Double-Blind, Placebo-Controlled Trial of Astelin® (azelastine hydrochloride) Nasal Spray, Zyrtec® (cetirizine), and Flonase® (fluticasone propionate) in Patients with Seasonal Allergic Rhinitis.

MedPointe- Randomized, Double-Blind Trial of Astelin® (azelastine hydrochloride) Nasal Spray Compared to Zyrtec® (cetirizine) in Patients with Seasonal Allergic Rhinitis.

Merck- A Multicenter, Double-Blind, Randomized, Parallel-Group Study Investigating the Clinical Effect of Montelukast in Patients With Perennial Allergic Rhinitis.

Merck- A Multicenter, Double-Blind, Randomized, Parallel-Group Study Investigating the Clinical Effect of Combination Montelukast/Loratadine in Patients with Seasonal Allergic Rhinitis who Have a History of Asthma.

Merck- A Multicenter, Double-Blind, Randomized, Parallel-Group Study Investigating the Clinical Effect of Montelukast in Patients With Seasonal Allergic Rhinitis-Spring Study.

Merck- A Multicenter, Double-Blind, Randomized Study Investigating the Clinical Effect of Montelukast on Allergic Rhinitis in Patients with Seasonal Allergic Rhinitis and Chronic Asthma - Spring 2003 Study.

Merck- A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Investigating the Clinical Effects of Montelukast in Patients with Perennial Allergic Rhinitis.

Merck- A Multicenter, Double-Blind, Randomized, Parallel-Group Study Investigating the Clinical Effects of Montelukast in Patients with Seasonal Allergic Rhinitis Over a 4-Week Treatment Period - Fall 2001.

Merck- A Multicenter, Double-Blind, Randomized, Parallel-Group Study Investigating the Clinical Effect of L-000888839 in Patients with Seasonal Allergic Rhinitis - a Pilot Study During the Fall Season.

Merck- A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Investigating the Clinical Effect of Montelukast in Patients with Perennial Allergic Rhinitis.

Merck - A 28-Day Study Evaluating the Safety of Ragweed (Ambrosia Artemisiifolia) Allergy Immunotherapy Tablet(SCH 39641/MK-3641) Treatment in Ragweed Allergic Adults.

Novartis- A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose (Subcutaneous Administrations Of 50 mg, 150 mg Or 300 mg), Multicenter, Dose-Ranging Trial To Assess The Efficacy, Safety, Tolerability, Phamacokinetics And Biological Effect Of Anti-Ige Recombinant Humanized Monoclonal Antibody E25 (Rhumaab-E25) Versus Placebo For Symptom Prevention In Patients With Ragweed Induced Seasonal Allergic Rhinitis.

Novartis- A phase IIIB, multicenter, multiple dose, 4-month, randomized, parallel-group, double-blind, placebo-controlled study to asses the efficacy, safety and tolerability of rhuMAb-25 for the treatment of symptomatic patients 12-75 years old with perennial allergic rhinitis.

Novartis- A Second Randomized, Double Blind, Placebo Controlled, Multicenter Study of the Efficacy, Safety, and Effect on Quality of Life of Zyrtec® (Cetirizine HCL) vs. Placebo in the Treatment of Seasonal Allergic Rhinitis.

Novartis- A 28 Week, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Omalizumab Administered Concomitantly with an Optimized Asthma Care Program in Patients with Allergic Asthma Already Demonstrating Inadequate Control Despite Currently Recommended Therapies.

Novartis- An Open-Label Extension to Provide Continuation of rhuMAb-E25 Treatment to Children with Allergic Asthma Who Participated in the One-Year Study.

Novartis- A Phase III, 7-Month, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multicenter Trial with a 5-Month Open-Label Extension Period to Assess Safety and Tolerability, Steroid-Reduction, Pharmacokinetics, and Pharmacodynamics of Subcutaneous rhuMAb-E25 in Children (6-12 Years) with Allergic Asthma Requiring Daily Treatment with Inhaled Corticosteroids.

Novartis- An Open-Label Extension Trial to Assess the Safety of rhuMAb-E25 in Patients with Seasonal Allergic Rhinitis Previously Treated in the Core Trial Protocol 6.

Perrigo Pharmaceuticals - A Blinded, Randomized, Vehicle-Controlled, Parallel-Group Multicenter Study to Demonstrate the Safety and Bioequivalence of Budesonide Nasal Spray, 32mcg (Perrigo Israel) Compared with Rhinocort Aqua (Budesonide) Nasal Spray 32mcg (AstraZeneca) in the Relief of Symptoms of Seasonal Allergic Rhinitis.

Pfizer- A Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-Center Study of the Efficacy and Safety of Cetirizine-Pseudoephedrine vs. Fexofenadine-Pseudoephedrine (ALLEGRA-D®) vs. Placebo in the Treatment of Subjects Twelve Years and Older With Seasonal Allergic Rhinitis.

Pfizer- A Multicenter, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Zyrtec-D 12 HourTM (Cetirizine HCI/Pseudoephedrine HCI) Versus Placebo in Patient with Seasonal Allergic Rhinitis and Concomitant Mild to Moderate Asthma.

Pfizer- A Second Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy, Safety, and Effect on Quality of Life of Zyrtec (Cetirizine HCI) vs. Placebo in the Treatment of Seasonal Allergic Rhinitis.

Pfizer- A Four Week, Double-Blind, Placebo-Controlled, Multi-Center Study of the Safety and Toleration of Certirizine-Pseudoephedrine in the Treatment of Seasonal Allergic Rhinitis in Adults and Children 12 Years of Age and Older.

Pozen- A Multicenter, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Zyrtec-D 12 Hour ® (Cetirzine HCI/Pseudoephedrine HCI) Versus Placebo in Patients with Seasonal Allergic Rhinitisand Concomitant Mild to Moderate Asthma.

Rigel Pharmaceuticals, Inc. - A Phase II Multi-Center, Randomized, Double-Blind, Active and Placebo-Controlled 7 Day Study of Mast Cell Inhibitor, R926112, in Patients with Symptomatic Seasonal Allergic Rhinitis.

Rhone-Poulenc Rorer Pharmaceuticals, Inc.- A Multicenter, Double-Blind, Placebo Controlled, Randomized Comparative Study to Compare the Efficacy and Safety of Ebastine 20mg, Ebastine 10mg, Loratadine 10mg, and Placebo all Given Once Daily for Four Weeks in the Treatment of Seasonal Allergic Rhinitis.

Schering Plough Research Institute - Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200mcg QD in the Relief of Nasal Congestion Associated with Seasonal Allergic Rhinitis. (2 trials/sister studies)

Schering Plough Research Institute - A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Long-Term Safety of Ragween (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adult Subjects with a history of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (2 trials/sister studies) - Allergic Rhinitis

Schering Plough/Merck - A Multicenter, Double-Blind, Randomized, Placebo-controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Grass (Phleum pratense) Sublingual Tablet (SCH 697243) in Subjects Between 5 and 65 Years of Age, With a History of Grass Pollen-Induced Rhinoconjunctivitis, With or Without Asthma - Allergic Rhinitis

Schering-Plough Research Institute -A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Grass (Phleum Pratense) Sublingual Tablet (SCH 697243) in Adult Subjects with a history of Grass Pollen-Induced Rhinoconjunctivitis With or Without Asthma - Allergic Rhinitis

Schering-Plough Research Institute - A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Sublingual Immunotherapy with SCH 697243 (Phleum Pratense) in Children 5 to < 18 years of age with a history of grass pollen-induced rhinoconjunctivitis with or without asthma - Allergic Rhinitis

**Schering-Plough Research Institute - Efficacy and Safety of Concurrent Administration of Mometasone Furoate Nasal Spray (MFNS) and Oxymetazoline Nasal Spray Administered Once Daily (QD) Vs. Oxymetazoline Twice Daily (BID), Mometasone Furoate QD, and Placebo in the treatment of subjects with Seasonal Allergic Rhinitis.

Stallergenes - A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of the Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Administered as Allergen Based Tablets Once Daily to Adult Patients Suffering From Grass Pollen Rhinoconjunctivitis - Allergic Rhinitis

Sunovion - A 6 Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group, SafetyStudy of the Potential Inhibitory Effects ofCiclesonide Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal Axis In Subjects 6-11 Years with Perennial Allergic Rhinitis.

Schering-Plough Research Institute - Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg QD in the Treatment of Seasonal Allergic Rhinitis.

Schering-Plough Research Institute - A Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Multicenter Study of Mometasone Furoate Nasal Spray on Sleep Disturbance and Daytime Somnolence in Subjects with Symptomatic Seasonal Allergic Rhinitis.

Schering-Plough Research - Efficacy and Safety of Combination Loratadine/Montelukast QD vs. Pseudoephedrine and Placebo in the Treatment of Subjects with Seasonal Allergic Rhinitis.

Schering-Plough - Pilot Efficacy and Safety Field Trial of Desloratadine Administered Concomitantly with Oxybutynin, in Subjects with Seasonal Allergic Rhinitis and Post-Nasal Drip.

Schering-Plough- A Placebo-and Active-Controlled Efficacy and Safety Study of a Once-Daily Fixed Combination Tablet of Desloratadine 5mg / Pseudoephedrine 120mg (SCH 483 (5/12)) in Subjects With Seasonal Allergic Rhinitis.

Schering-Plough- A Double-Blind, Placebo-Controlled Study of the Effect of Desloratadine in Subjects With Perennial Allergic Rhinitis.

Schering-Plough- A Study of the Effect of Desloratadine 5 mg and Pseudoephedrine 240 mg on Nasal Stuffiness in Subjects with Seasonal Allergic Rhinitis.

Schering-Plough- Dose Ranging Study of Mometasone Furoate HFA-227 Nasal Aerosol in the Treatment of Patients with Seasonal Allergic Rhinitis.

Schering-Plough- Efficacy and Safety of Desloratadine 5 mg Tablet in the Treatment of Subjects 12 to 17 Years of Age with Seasonal Allergic Rhinitis.

Schering-Plough- Efficacy and Safety of SCH 34117 + Pseudoephedrine, BID, vs its Components in the Treatment of Subjects with Seasonal Allergic Rhinitis.

Schering-Plough- Efficacy and Safety of SCH 34117 in Patients with Seasonal Allergic Rhinitis.

Schering-Plough- Efficacy and Safety of SCH 34117 in Subjects With Seasonal Allergic Rhinitis and Concurrent Asthma.

Schering-Plough- Efficacy and Safety of SCH 34117 in the Prophylasis of Subjects with Seasonal Allergic Rhinitis.

Schering-Plough- Efficacy and Safety of Two Formulations of SCH 483 Compared to Desloratadine and Pseudoephedrine in the Treatment of Subjects with Seasonal Allergic Rhinitis.

Schering-Plough- Efficacy and Safety of Combination Loratadine/Montelukast QD vs. Its Components in the Treatment of Subjects With Seasonal Allergic Rhinitis.

Schering-Plough- Safety and Efficacy of Claritin® in Lessening the Severity of Asthma Exacerbation Associated with Seasonal Allergic Rhinitis.

Schering-Plough- Safety and Efficacy of Mometasaone Furoate Nasal Spray in Lessening the Severity of Asthma Exacerbation Associated with Seasonal Allergic Rhinitis (SAR).

Schering-Plough- A Placebo- and Active Controlled Efficacy and Safety Study of a Once-Daily Fixed Combination Tablet of Desloratadine 5 mg/Pseudoephedrine 120 mg (SCH 483 [5/120]) in Subjects with Seasonal Allergic Rhinitis.

Schering-Plough- A Study of the Effects of Desloratadine in the Quality of Life of Subjects with Disordered Sleep Associated with Symptomatic Seasonal Allergic Rhinitis (SAR).

Schering-Plough- Pilot Study to Investigate the Efficacy and Safety of a Combination of Desloratadine 5 mg QD Plus Pseudoephedrine 120 mg Sustained Release Versus a Combination of Loratadine 10 mg Plus Pseudoephedrine 240 mg QD Sustained Versus Placebo, In Subjects with Seasonal Allergic Rhinitis.

Schering-Plough- Screening Protocol to Identify Subjects Who Exhibit Difficulty in Tolerating a High Dose of Pseudoephedrine. (Seasonal Allergic Rhinitis)

Schering-Plough- Efficacy and Safety of Two Formulations of SCH 483 5/240 mg Compared to Desloratadine 5 mg and Pseudoephedrine 240 mg QD Sustained Release, in the Treatment of Subjects with Seasonal Allergic Rhinitis.

Schering-Plough- Efficacy and Safety of Two Formulations of SCH 483 5/240 mg Compared to Desloratadine 5 mg and Pseudoephedrine 240 mg QD Sustained Release, in the Treatment of Subjects with Seasonal Allergic Rhinitis.

Schering-Plough- Efficacy and Safety of SCH 34117 vs. Placebo in the Treatment of Patients with Perennial Allergic Rhinitis.

Schering-Plough- Four-Week, Double-Blind, Safety and Efficacy Study of Beclomethasone Dipropionate Nasal Aerosol vs. Placebo in Children (age 3-5) with Perennial and/or Seasonal Allergic Rhinitis.

Schering-Plough- A Double-Blind, Placebo-Controlled Comparison of the Safety and Efficacy of Claritin vs. Fexofenadine vs. Placebo in the Treatment of Subjects with Seasonal Allergic Rhinitis.

Schering-Plough- Safety and Severity of Mometasone Furoate Nasal Spray in Lessening the Severity of Asthma Exacerbation Associated with Seasonal Allergic Rhinitis.

Sepracor- A Twelve-Month Safety Study of Norastemizole QD in Subjects with Perennial Allergic Rhinitis/Seasonal Allergic Rhinitis.

Sepracor- The Evaluation of Norastemizole(30 mg) and Loratadine when Administered to Subjects with Seasonal Allergic Rhinitis. A Double-Dummy, Double-Blind, Placebo-Controlled, Parallel Group Study.

Sepracor- The Evaluation of Three Norastemizole Doses (15 mg, 30 mg, 45 mg) and Loratadine when Administered to Subjects with Seasonal Allergic Rhinitis.

Sepracor- The Evaluation of Three Norastemizole Doses (30 mg, 60 mg, 90 mg) and Loratadine when Administered to Subjects with Seasonal Allergic Rhinitis. A Multi-Dose, Double-Dummy, Double-Blind, Placebo-Controlled, Parallel Group Study.

Sepracor- A Multi-Dose, Double-Dummy, Double-Blind, Placebo-Controlled, Parallel Group Study: The Evaluation of Three Norastemizole Doses (15mg, 30mg, 45mg) and Loratadine with Administered to Subjects with Seasonal Allergic Rhinitis.

SmithKline Beecham- A Double-Blind, Double-Dummy, Placebo-Controlled, Randomized, Parallel Group Study to Examine the Effects of Oral SB205312 300mg BID in Patients with Asthma and Concomitant Seasonal Allergic Rhinitis - A Comparison to Patients Taking Inhaled Vanceril 168 mcg BID and as Required Nasal Rescue Medication.

Sunovion - A 2-Week Randomized, Double Blind, Placebo Controlled, Parallel Group, Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6 to 11 Years with Seasonal Allergic Rhinitis.

Sunovion - A 12-Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years with Perennial Allergic Rhinitis.

Teva - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Study to Assess the Long-Term Efficacy and Safety of BDP HFA Nasal Aerosol (320mcg QD) in Adult and Adolescent Subjects (12 and older) with Perennial Allergic Rhinitis.

Teva - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center, Dose- Finding Study To Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Pediatric Subjects (6 to 11 years of age) With Seasonal Allergic Rhinitis (SAR).

UCB Pharma, Inc.- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study Comparing the Efficacy and Safety of Three Doses (4mg, 15mg, or 60mg) of ucb 28754 (efletirizine dihydrochloride), Administered Twice a Day for 7 Days, to Placebo in Adult Outpatients with Seasonal Allergic Rhinitis caused by Ragweed Pollen.

Zeneca- A Multicenter, Randomized, Double-blind, Placebo-Controlled Trial to Assess the Safety and Efficacy of Zafirlukast (ACCOLATE®) and Loratadine in Subjects with Seasonal Allergic Rhinitis.

Allergic Rhinitis/Chronic Urticaria

UCB, Inc. - A Multi-Center, Randomized, Doubl-Blind, Placebo Controlled Parallel Group Study of the Safety of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months (Allergic Rhinitis or Chronic Urticaria)

UCB, Inc. - A Multi-Center, Randomized, Double-Blind, Placebo Controlled Parallel Group Study of the Safety of Levocetirizine Dihydrochloride Oral Liquid Formulation b.i.d. Dosing in Children Aged 2 to 6 years suffering from Allergic Rhinitis or Chronic Urticaria or Unknown Origin,

Respiratory Research Experience

Asthma

3M- A 12-week Comparison of Daily Doses of 100 mcg and 200 mcg of HFA-134a Beclomethasone Dipropionate versus Placebo in Pediatric Patients with Symptomatic Asthma.

3M- Exercise Challenge Dose Response Study of HFA-134a Butixocort Propionate, CFC-11/12 Beclomethasone Dipropionate and HFA-134a Placebo in Patients with Reversible Obstructive Airway Disease Asthma

3M- Dose Response Comparison of HFA-134a Beclomethasone Autohaler® Inhalation Device with HFA-134a Beclomethasone Press & Breathe MDI in Patients with Asthma.

3M- Dose Response Comparison of HFA-134a Beclomethasone Dipropionate with CFc-11/12 Beclomethasone Dipropionate in Patients with Asthma.

3M- Safety and Efficacy Study of HFA-134a Albuterol Sulfate Delivered from a Press-and-Breathe MDI, HFA-134a Albuterol Sulfate Delivered from the Autohaler® Inhalation Device, and HFA-Placebo in Patients with Asthma.

3M- A 12-Week Comparison of Daily Doses of 100 mcg and 200 mcg of HFA-134a Beclomethasone Dipropionate in the AutohalerTM Device Versus Placebo in Pediatric Patients with Symptomatic Asthma.

3M- A 6 & 12 Month, Open Label, Safety and Efficacy Study of HFA134a Beclomethasone Dipropionate (BDP) in Pediatric Patients with Asthma.

Abbott Laboratories- Long Term Surveillance of Zileuton Plus Usual Care Versus Usual Care in Patients with Asthma 5-Lipoxygenase Inhibitor.

Abbott Laboratories- Phase III Safety Study of ABT-761 in Patients Completing Protocol M95-411. (Asthma)

Abbott Laboratories- Phase III Study of the Efficacy of Zileuton 1200 mg BID, Controlled-Release (CR), and 600 mg QID, Immediate Release (IR), and Placebo in Patients with Moderate Asthma.

Abbott Laboratories- Phase III Study of the Safety and Efficacy of ABT-761 150 mg, 300 mg QD versus Placebo in Moderate Asthma.

Abbott Laboratories- A Study of the Genetic Component of ALT Evaluation in Patients Previously Treated with Zileuton (Zyflo). (Asthma)

Actelion - A multi-center, double-blind, placebo-controlled, parallel-group study to establish proof-of-concept and explore the efficacy of different doses of ACT-129968 in adult patients with partly controlled asthma.

Altana Pharma - Pharmacokinetics of Repeated Oral Doses of 250mcg, 375mcg and 500mcg Roflumilast in Children and Adolescents with Mild to Moderate Asthma and Healthy Adult Subjects.

Altana Pharma - A Randomized, Controlled Study of Roflumilast (250 mcg and 500 mcg) Versus Placebo in Patients with Asthma.

Amgen - A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Phase 2 Study to Determine the Safety and Efficacy of AMG 317 in Subjects with Moderate to Severe Asthma.

Aradigm Corporation- Effectiveness of the SmartMist Asthma Management System Combined with Inhaled Fluticasone Propionate vs. Aerochamber with Fluticasone Propionate in Moderate and Severe Asthmatics.

Array - A Phase 2 Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of ARRY-502 in Adults with Persistent Asthma.

AstraZeneca - A 6-Month Randomized, Double-Blind, Parallel-Group, Multicentre, Placebo-Controlled Phase II Study to Compare Anti-Asthmatic Effect and Safety of Esomeprazole (Nexium) 40 mg Twice Daily or 40 mg Once Daily with Placebo in Adults with Asthma.

AstraZeneca - A Multicenter, Randomized, Open-Label Study to Assess the Functionality of the SYMBICORT® pMDI with an Actuation Counter During Use by Children, Adolescents, and Adults with Stable, Inhaled Corticosteroid-Dependent Asthma.

AstraZeneca- A Randomized, Double-Blind, Active-Controlled, Parallel-Group, Single-Dummy, Multicenter, 12 Week Study to Assess the Efficacy and Safety of SYMBICORT® pMDI 160/4.5 μg x 2 Actuations Once-Daily (QD) Compared to SYMBICORT pMDI 80/4.5 μg x 2 Actuations QD, SYMBICORT pMDI 80/4.5 μg x 2 Actuations Twice-Daily (BID) and to Budesonide pMDI 160 μg x 2 Actuations QD in Asthmatic Subjects 12 Years of Age and Older.

AstraZeneca-A Twelve-Week, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Trial of Symbicort® (80/4.5 mcg) versus its Mono-Products (budesonide and formoterol) in Children (> 6 Years of Age) and Adults with Asthma - SPRUCE 80/4.5.

AstraZeneca-A Twelve-Week, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Trial of Symbicort® (160/4.5 mcg) versus its Mono-Products (budesonide and formoterol) in Adolescents (> 12 Years of Age) and Adults with Asthma - SPRUCE 160/4.5.

AstraZeneca-A Twelve-Week, Randomized, Double-Blind, Double-Dummy, Trial of Symbicort® (40/4.5 mcg) versus its Mono-Products (budesonide and formoterol) in Asthmatic Children Aged Six to Fifteen Years - Seedling 40/4.5.

AstraZeneca- START-Inhaled Steroid Treatment as Regular Therapy in Early Asthma.

AstraZeneca- A Randomized, Double-Blind, Parallel-Group Multicenter Efficacy and Safety Phase IIB Pilot Study of Esomeprazole 40 mg Twice Daily Versus Placebo Twice Daily in Adult Asthmatics Treated for 4 Months.

AstraZeneca- A Placebo-Controlled Comparison of the Efficacy, Safety and Pharmacokinetics of the Current US Version of Pulmicort (Budesonide) Turbuhaler® and the New Version of Pulmicort Turbuhaler® in Asthmatic Children and Adolescents.

AstraZeneca- A Three-Year Open-Label Safety Study of Budesonide (Pulmicort) Nebulizing Suspension in Asthmatic Children.

AstraZeneca- Twelve-Week, Randomized, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Study of SYMBICORT® pMDI Administered Once Daily in Adults and Adolescents with Asthma - STEM

AstraZeneca- A 52-Week, Randomized, Double-Blind, Single-Dummy, Parallel-Group, Multicenter Phase III Study Comparing the Long-Term Safety of SYMBICORT® pMDI 160/4.5 µg X 4 Actuations Twice Daily to SYMBICORT® pMDI 160/4.5 µg X 2 Actuations Twice Daily and Budesonide HFA pMDI 160 µg X 4 Actuations Twice Daily in Adult and Adolescent Subjects with Asthma.

AstraZeneca - A Randomized, Partly Blinded, Multicenter, Parallel Study Comparing the Efficacy and Safety of PULMICORT RESPULES® (budesonide inhalation suspension) at 0.5 mg QD, 1.0 mg QD, 1.0 mg BID, 2.0 mg BID and PULMICORT TURBUHALER® (budesonide) at 400 mcg BID in Adolescents (12 Years of Age and Older) and Adults with Moderate to Severe Asthma.

AstraZeneca - A Placebo-Controlled Comparison of the Efficacy and Safety of the Current US Version of Pulmicort (Budesonide) Turbuhaler® and the New Version of Pulmicort Turbuhaler® in Asthmatic Adults Currently Treated with Inhaled Steroids.

Aventis Pharmaceuticals - A Placebo- and Active-Controlled (ciclesonide metered-dose inhaler), Randomized, Parallel-Group, Dose-Range Finding Study of Ciclesonide Administered by Dry Powder Inhaler (Ultrahaler®) in Adult and Adolescent Patients with Persistent Asthma.

Aventis- A Phase III Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Efficacy, Safety and Dose Response Study of Ciclesonide Metered Dose Inhaler 100 µg/day, 200 µg/day, and 400 µg/day (Ex-Valve) Administered Once Daily For 12-Weeks In The Treatment of Mild To Moderate Persistant Asthma In Adolescents and Adults.

Aventis- A Phase III double-Blind, Double-Dummy, Parallel-Group, Multicenter, Placebo-Controlled, Efficacy And Safety Study of Ciclesonide MDI 400 µg/day, 800 µg/day (EX-Valve) and Flovent ® MDI (Fluticasone Propionate) 880 µg/day (EX-Actuator). (Asthma) Administered Twice Daily For 12-Weeks In The Treatment of Severe Persistent Asthma In Adolescents And Adults.

Aventis- A Multicenter, Double-Blind, Randomized, One Year, Long-Term Safety Study Of Ciclesonide 400 µg/day to 800 µg/day (Ex-Valve) or QVAR 320 µg/day to 640 µg/day (EX-Actuator) Metered Dose Inhaler Administered Twice Daily For the Treatment of Severe Persistent Asthma In Adolescents And Adults.

Aventis- A Phase III Double-Blind, Parallel-Group, Multicenter, Placebo-Controlled Study of Ciclesonide MDI 800 µg/day and 1600 µg/day Administered Twice Daily for 12 Weeks to Determine the Effectiveness of Ciclesonide to Reduce Oral Corticosteroid (OCS) Use in Oral Corticosteroid-Dependent Patients With Severe Persistent Asthma.

Aventis- A Phase III Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Efficacy, Safety and Dose Response Study of Ciclesonide Metered Dose Inhaler 50 µg/day, 100 µg/day, and 200 µg/day (EX-Valve) Administered Once Daily for 12 Weeks in the Treatment of Children with Persistent Asthma.

Aventis- A Multicenter, Randomized, Open-Label, One Year Long-Term Safety Study of Ciclesonide Metered Dose Inhaler 50 µg/day to 200 µg/day (Ex-Valve) Administered Once Daily or Fluticasone Dry Powder Inhaler (Flovent ® Rotadisk®) 50 µg or 100 µg Administered Twice daily For the Treatment Of Children With Persistent Asthma.

Aventis-A Phase III, Multicenter, Double-Blind, Placebo Controlled, Non-Inferiority Study Assessing the Effects of Ciclesonide Metered Dose Inhaler 50 µg/day and 200 µg/day (Ex-Valve) Administered Once Daily on Growth in Children with Mild Persistent Asthma.

Aventis- A Multicenter, Open-Label, Randomized, Parallel Groups Study to Assess the Long Term Safety Performance of Fexofenadine Compared to Montelukast in Subjects with Asthma.

Aventis- A Multicenter, Double-Blind, Randomized, Parallel Groups Placebo-Controlled Study to Assess the Efficacy and Safety of Fexofenadine 120 mg BID in Subjects with Mild to Moderate Persistent Asthma.

Aventis- A Multicenter, Double-Blind, Randomized, Parallel Groups Placebo-Controlled Pilot Study To Observe The Effects Of Montelukast 10 mg In Combination With Fexofenadine 180 mg Daily Or 120 mg Bid On Asthma In Subjects With Persistent Mild To Moderate Atopic Asthma.

Aventis- A Multicenter, Open-Label, Long-Term (1 year) Safety Study of Ciclesonide 100 µg/Day (Ex-Valve) Metered Dose Inhaler Administered Once Daily for the Treatment of Mild to Moderate Persistent Asthma in Adolescents and Adults.

Aventis- A Pilot Study to Observe the Effects of Montelukast in Combination with Fexofenadine on Asthma in Subjects with Persistent Mild to Moderate Asthma.

Aventis- Phase III, Multicenter, Double-Blind Parallel Group Study Assessing the Effects of Triamcinolone Acetonide HFA-134a MDI on Growth in Asthmatic Children.

Aventis- A Twelve Week, Randomized, Double-Blind, Parallel Group Trial Comparing the Efficacy, Safety, and Tolerability of a 20 mg Daily Dose of IPL512,602 Oral Tablets to Placebo in Subjects with Mild to Moderate Persistent Asthma.

Aventis - A Multicenter, Multinational, Randomized, Double-Blind, Parallel Group Study of the Effects of Ciclesonide HFA-MDI 640 µg/Day and Beclomethasone HFA-MDI 640 µg/Day on Lens Opacification in Adult Subjects with Moderate to Severe Persistent Asthma.

Bayer- A Randomized, Double-Blind, Parallel Group Comparison of the Safety and Efficacy of Two Doses of BAY x 7195 Aerosol with Placebo in Patients with Asthma.

Bio-Pharm- Exercise Challenge Dose Response Study of HFA-134a Butixocort Propionate, CFC-11/12 Beclomethasone Dipropionate and HFA-134a Placebo in Patients with Reversible Obstructive Airway Disease. (Asthma)

Boehringer-Ingelheim - A Multicenter, Randomized, Study Starting with a4-week, 2way Crossover Double-Blind Treatment Phase Comparing the Efficacy and Safety of Combivent CFC MDI to Albuterol HFA MDI Followed by a 4-Week Open-Label CombiventRespimat Treatment Phase Whenall study drugs are Used for Symptom Relief "as needed" in Patients with Moderate to Severe Asthma.

Boehringer Ingelheim - A Phase III, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered via Respimat® Inhaler (5µg/day) Over 48 Weeks as Add-On Controller Therapy on Top of Usual Care in Patients with Severe Persistent Asthma.

Boehringer Ingelheim -A Phase III Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered via Respimat® Inhaler (2.5 and 5 µg Once Daily) Compared with Placebo and Salmeterol HFA MDI (50 µg Twice Daily) Over 24-Weeks in Patients with Moderate Persistent Asthma.

Boehringer Ingelheim -A Randomized, Double-Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-Week Treatment with Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-Naïve Patients with Persistent Asthma.

Byk Gulden - 12 Weeks Treatment with 125 µg Roflumilast versus 250 µg Roflumilast versus Placebo in Patients with Asthma.

Byk Gulden- A Placebo Controlled, Double-Blind, Double-Dummy, Multicenter, 6 Weeks Study of Orally Administered 60 mg BYK33043 in the Treatment of Adult Patients with Asthma Compared to Treatment with 176 mg Fluticasone Propionate.

Byk Gulden- 12 Weeks Treatment with 200 or 800 mcg Ciclesonide Versus Placebo Followed by a 40 Week Treatment with Ciclesonide in Asthmatic Patients. A Double-Blind, Randomized Parallel Group Study with an Open Label Extension.

Centocor, Inc. - A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Evaluating the Efficacy and Safety of CNTO 148 Administered Subcutaneously in Symptomatic Subjects with Severe Persistent Asthma.

Cephalon -A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma.

Ception - An Efficacy and Safety Study of Reslizumab (CTX55700) in the Treatment of Poorly Controlled Asthma in Subjects with Eosinophilic Airway Inflammation.

Ciba-Geigy Ltd- A Double Blind, Randomized, Parallel-Group, Placebo-Controlled, Multiple-Dose (Intravenous Infusions Of 35 Mg, 58 Mg, 93mg Cgp 51901 q 2 Weeks X 6) Multicenter Pilot Trial To Assess The Efficacy, Safety, Tolerability, Pharmacokinetics, And Biologic Activity Of CGP 51901 In Patients 18-40 Years Old With Milt To Moderate Perennial Allergic Asthma.

Ciba-Geigy Ltd- A Twelve-Month, Double-Blind, Between-Patient, Placebo-Controlled Trial Comparing the Safety, Tolerability and Efficacy of 12 ug and 24 ug Twice Daily Formoterol Dry Powder Capsules for Inhalation Delivered by a Single-Dose Inhaler (Aeroliser ®) in Children With Asthma in Need of Daily Treatment With Inhaled Bronchodilators and Anti-Inflammatory Treatment.

Ciba-Geigy Ltd.- A Twelve-Month, Double-Blind, Between-Patient, Placebo-Controlled Trial Comparing The Safety, Tolerability And Efficacy Of 12 µg And 24 µg Twice Daily Formoterol Dry Powder Capsules For Inhalation Delivered By A Single-Dose Inhaler (Aeroliser®) In Children With Asthma In Need Of Daily Treatment With Inhaled Bronchodilaters And Corticosteroids.

Compleware- Single-Dose Study of the Pharmacokinetics of PLT 3514 Dietary Supplement in Asthmatic Children Ages 12-17 Years.

Compleware- Single-Dose Study of the Pharmacokinetics of PLT 3514 Dietary Supplement in Asthmatic Children Ages 6-11 Years.

Critical Therapeutics Inc. -A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Zileuton Controlled-Release (CR) Tablets Versus Placebo in Adult Patients with Asthma Poorly Controlled on Moderate Dose Inhaled Corticosteroids (ICS).

Dey Laboratories- A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Low Dose Albuterol Sulfate Inhalation Solution for Pediatric Subjects with Asthma.

Dura Pharmaceuticals- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Dose, Multicenter, 12-Week Study to Compare the Safety and Efficacy of Beclomethasone Dipropionate via the ìTo-Be-Marketedî SPIROS® Dry Powder Inhaler to VANCERIL® Metered-Dose Inhaler in Patients with Asthma.

Epigenesis - A 28-Day Randomized, Double-Blind, Dose-Response Study in Steroid Na®ve Asthmatics Given Inhaled EPI-12323 Once Daily, or Placebo to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy with a Placebo Run-In Period.

Forest Laboratories- A Double Blind, Placebo Controlled, Long Term Growth Study of HFA Flunisolide in Children with Mild Asthma.

Forest Laboratories- Aerobid-Once-A-Day With Aerochamber in Mild to Moderate Asthma Patients.

Genentech, Inc. - An Epidemiologic Study of Xolair® (omalizumab): Evaluating Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma(Excels).

Genentech - A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate Lebrikizumab (MILR1444a) In Adult Patients with Asthma Who Are Not Taking Inhaled Corticosteroids.

Genentech - A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluated The Safety, Tolerability And Efficacy of Lebrikizumab (MILR1444a) In Adult Patients with Asthma Who Are Inadequately Controlled on Inhaled Corticosteroids.

Genentech - A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients with Uncontrolled Asthma Who are on Inhaled Corticosteroids and a Second Controller Medication.

Genentech - A Phase IIB, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy, Safety, And Dosing Regimens Of MEMP1972A In Adults With Allergic Asthma Who Are Inadequately Controlled on Inhaled Corticosteroids and a Second Controller (COSTA).

GlaxoSmithKline - A randomised, double-blind, placebo-controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents.

GlaxoSmithKline - A randomised, double-blind, parallel group, multicentre study ofFluticasone Furoate/GW642444 Inhalation Powder, Fluticasone Furoate Inhalation Powder alone, and Fluticasone Propionate alone in the treatment of persistent asthma in adults and adolescents

GlaxoSmithKline - A Randomized, Double-Blind, Placebo-Controlled , Two-Way Crossover 7-Day Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Dose Inhaled GW642444 25 µg in Children Aged5-11 Years with Persistent Asthma

GlaxoSmithKline - A Randomized, Double-Blind, Placebo-Controlled , Two-Way Crossover 14-Day Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Dose Inhaled Fluticasone Furoate 100 mcg in Children Aged 5-11 Years with Persistent Asthma

GlaxoSmithKline - A Repeat-Dose, Open-Label, 2-Session Study to Assess the Systemic Exposure to, and Pharmacodynamics of, Fluticasone Propionate HFA Inhalation Aerosol 88 mcg Administered Twice-Daily for 28 Days Delivered via an MDI and Valved Holding Chamber with Infant Facemask to Subjects Ages 6 Months to >12 Months Who Have Experienced 2 or More Wheezing Episodes in the Proceeding 6 Months.

GlaxoSmithKline - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Repeat Dose Study to Assess the Effect of SB-480848 on Overall Asthma Control in Adult Subjects with Persistent Asthma Controlled on Stable, Low-Dose, Inhaled Corticosteroids.

GlaxoSmithKline - A Dose-Ranging Study of Vilanterol (VI) Inhalation Powder in Children Aged 5-11 Years with Asthma on a Background of Inhaled Corticosteroid Therapy.

GlaxoSmithKline - A Dose-Ranging Study of Fluticasone Furoate (FF) Inhalation Powder in Children Aged 5-11 Years With Asthma.

GlaxoSmithKline - A 6-Month Safety and Benefit Study of Inhaled Fluticasone Propionate/Salmeterol Combination Versus Inhaled Fluticasone Propionate in the Treatment of 6,200 Pediatric Subjects 4-11 Years Old With Persistent Asthma.

Glaxo- A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Placebo-Controlled, Six Month Clinical Trial to Examine the Efficacy and Safety of Salmeterol Xinafoate 42mcg BID, Beclomethasone Dipropionate 84mcg QID, and Placebo in Adolescent and Adult Subjects with Mild to Moderate Asthma.

Glaxo- A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Evaluation of the Effect of Salmeterol on Methacholine-Induced Bronchial Hyperresponsiveness over Twenty-Four Weeks in Adolescent and Adult Subjects with Asthma.

GlaxoSmithKline- A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group, Multicenter Clinical Trial of Four Weeks Treatment with SEREVENT Inhalation Aerosol, 25mcg BID, 50mcg BID, and Placebo Administered Via a Valved Holding Chamber with Facemask in Subjects with Asthma Age 6 to 23 Months.

GlaxoSmithKline- A Multi-Center, Randomized, Double-Blind, Parallel Group, 40-Week Comparison of Asthma Control Using Bronchial Hyperresponsiveness as an Additional Guide to Long Term Treatment in Adolescents and Adults Receiving Either Fluticasone Propionate / Salmeterol DISKUS BID or Fluticasone Propionate DISKUS BID (or Placebo BID if Asymptomatic).

Glaxo Wellcome- A 12-Month, Open-Label Trial to Asses the Long-Term Safety of Albuterol 200mcg QID in GR106642X Propellant via the MDI in Adolescent and Adult Subjects with Asthma.

Glaxo Wellcome- A Comparison of Adding Serevent® Versus Doubling The Dose of Beclovent® in Asthmatic Subjects Symptomatic on their Existing Inhaled Corticosteroids.

Glaxo Wellcome- A Double-Blind, Parallel Group Evaluation of the Efficacy and Quality of Life Outcomes of Salmeterol Versus Placebo in Asthma Subjects.

Glaxo Wellcome- A Randomized, Double-Blind, Double-Dummy, Comparative Clinical Trial of Salmeterol 50mcg BID via Diskus® and Salmeterol 50mcg BID via the Metered-Dose Inhaler Versus Placebo For Twelve Weeks in Adolescent and Adult Subjects with Mild to Moderate Asthma.

Glaxo Wellcome- A Randomized, Double-Blind, Double-Dummy, Parallel Group Comparison of Inhaled Propionate (88mcg BID) versus Zafirlukast (20mg BID) over 12 Weeks in Subjects with Persistent Asthma.

Glaxo Wellcome- A Randomized, Double-Blind, Double-Dummy, Parallel Group, Comparative Study of Inhaled Fluticasone Propionate (88mcg BID) Versus Zafirlukast (20mg BID), in Subjects who are Currently Receiving Beta Agonists Alone. (Asthma)

Glaxo Wellcome- A Randomized, Double-Blind, Parallel Group Comparison of Inhaled Fluticasone Propionate (88mcg BID) With Oral Zafirlukast (20mg BID) in Subjects With Mild to Moderate Asthma.

Glaxo Wellcome- A Randomized, Double-Blind, Parallel-Group Study Evaluating the Protective Effects of the Salmeterol Xinafoate/Fluticasone Propionate Combination Product (50/100 mcg BIDD via DISKUSÜ) Against Bronchospasms Induced by Activity as Measured by Exercise Challenge Testing in Adolescent and Adult Subjects who Require Chronic Inhaled Corticosteroid Therapy for the Treatment of Persistant Asthma.

Glaxo Wellcome- A Randomized, Double-Blind, Parallel-Group Study Evaluating the Protective Effects of the Salmeterol Xinafoate/Fluticasone Propionate Combination Product (50/250mcg BID via DISKUSÜ) Against Bronchospasms Induced by Activity as Measured by Exercise Challenge Testing in Adolescent and Adult Subjects who require Chronic Inhaled Corticosteroid Therapy for the Treatment of Persistent Asthma.

Glaxo Wellcome- A Randomized, Double-Blind, Parallel-Group Trial Evaluating Safety and Efficacy of Salmeterol 50mcg BID and Fluticasone Propionate 100mcg BID Individually and in Combination and Placebo in Subjects with Asthma.

Glaxo Wellcome- A Randomized, Double-Blind, Parallel-Group, Comparative Trial of Inhaled Fluticasone Propionate via the Multi-Dose Powder Inhaler 250mcg BID, 500mcg QD and Placebo in Adolescent and Adult Subjects with Mild to Moderate Asthma.

Glaxo Wellcome- Randomized, Double-Blind, Double-Dummy, Parallel-Group Trial Assessing the Efficacy and Safety of Fluticasone Propionate 50 or 100mcg BID via the Multi-Dose Powder Inhaler, Fluticasone Propionate 50 or 100mcg BID via the Diskhaler® and Placebo in Subjects aged 4 to 11 years with Chronic Asthma.

Glaxo Wellcome- A Randomized, Double-Blind, Parallel Group, Comparative Trial of Salmeterol/Fluticasone Propionate Combination Product 50/100mcg DISKUS Inhaler BID Versus Fluticasone Propionate 250mcg DISKUS Inhaler BID in Adolescents and Adults with Moderate Persistent Asthma.

Glaxo Wellcome- A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 12 Week Trial of Inhaled Fluticasone Propionate 88mcg BID, 220mcg BID and 440mcg BID Versus Placebo in Propellant GR106642X in Adolescents and Adult Subjects with Asthma who are Maintained on Bronchodilator Therapy.

Glaxo Wellcome- A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 12 Week Trial of Inhaled Fluticasone Propionate 88mcg BID, 220mcg BID and 440mcg BID Versus Placebo in Propellant GR106642X in Adolescents and Adult Subjects with Asthma who are Maintained on Inhaled Corticosteroid Therapy.

Glaxo Wellcome- A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group, Comparative Study of Inhaled Fluticasone Propionate (88mcg BID) Versus Zafirlukast (20mg BID), in Subjects Who are Currently Receiving Beta-Agonists Alone. (Asthma)

Glaxo Wellcome- A Randomized, Double-Blind, Parallel-Group Trial Evaluating Safety and Efficacy of Salmeterol 50 mcg BID and Fluticasone Propionate 250 mcg BID Individually and in Combination and Placebo in Subjects with Asthma.

Glaxo Wellcome- A Randomized, Double-Blind, Parallel Group Comparative Trial of Inhaled Fluticasone Propionate (84mcg and 210mcg BID) and Beclomethasone Dipropionate (168mcg and 336mcg BID) via the Metered-Dose Inhaler in Asthmatic Subjects Previously Treated with Beclomethasone Dipropionate.

GlaxoSmithKline- A Multi-Center, Randomized, Double-Blind, Parallel Group, 40-Week Comparison of Asthma Control Using Bronchial Hyperresponsiveness as an Additional Guide to Long Term Treatment in Adolescents and Adults Receiving Either Fluticasone Propionate / Salmeterol DISKUS BID or Fluticasone Propionate DISKUS BID (or Placebo BID if Asymptomatic).

GlaxoSmithKline - A Stratified, Multicenter, Randomized, Double-Blind, Parallel Group, 4-Week Comparison of Fluticasone Propionate / Salmeterol DISKUS Combination Product 100/50mcg BID versus Fluticasone Propionate DISKUS 100mcg BID in Pediatric Subjects with Activity-Induced Bronchospasm.

GlaxoSmithKline- A Multicenter, Randomized, Double-Blind, Parallel Group, 40-Week Comparison of Asthma Control Using Bronchial Hyperresponsiveness as an Additional Guide to Long-Term Treatment in Adolescents and Adults Receiving Either Fluticasone Propionate / Salmeterol DISKUS BID or Fluticasone Propionate DISKUS BID (or placebo BID if Asymptomic.

Hoffman LaRoche - Effect of 24 Week Treatment with Ro 27-2441 Versus Placebo and Montelukast as Add-On Therapy to Inhaled Fluticasone Followed by 24 Week Extension Treatment in Persistent Asthma.

Hoffman LaRoche- Inhaled Corticosteroid Replacement Study - Efficacy and Safety of Ro 27-2441 in Moderate Persistent Asthma - Phase II.

Hoffman LaRoche- Dose-Ranging Study of Ro 27-2441 in Patients with Persistent Asthma not Treated with Inhaled Corticosteroids - Phase II.

Hoffman LaRoche - A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Single -Ascending Dose Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of RO50365050 (R1671) Following Intravenous Infusion in Subjects with Mild Intermittent Asymptomatic Asthma.

Icagen, Inc. - A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Assess the Safety and Efficacy of Four weeks of Oral Senicapoc Administration on Exercise-Induced Asthma.

Immunex- Phase II Safety and Efficacy Study of Daily Dosing with Nebulized Recombinant Human IL-4 Receptor in Asthma.

Immunex- Phase II Safety and Efficacy Study of Nebulized Recombinant Human IL-4 Receptor in Asthma Patients Using Inhaled Corticosteroids.

Integrated Therapeutics Group- Efficacy and Safety of Nasonex® vs. Placebo in Subjects with SAR and Concomitant Asthma.

Integrated Therapeutics Group- A Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Treatment of Seasonal Allergic Rhinitis (SAR) in Subjects with Co-Morbid Asthmaand a History of Seasonal Exacerbations of Asthma of Medical Resources Utilization (for Asthma and SAR).

IVAX Research, Inc. - Chronic-Dose Safety and Efficacy Study of Albuterol-HFA-BAI (ProAir HFA (Albuterol Sulfate) Breath Actuated Inhalation Aerosol) in Pediatric Asthmatics.

IVAX- Safety and Efficacy Evaluation of Two Doses of HFA-Propelled Beclomethasone Dipropionate (QVAR®) Versus Placebo by Breath Operated and Metered Dose Inhalers in Moderate Asthmatic Adolescents and Adults on a Stable Regimen of Inhaled Corticosteroids.

IVAX- Safety and Efficacy Evaluation of Two Doses of HFA-Propelled Beclomethasone Dipropionate (QVAR®) Versus Placebo by Breath Operated and Metered Dose Inhalers in Mild to Moderate Asthmatic Children.

Johnson & Johnson - A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Exploratory Study of the Safety and Efficacy of JNJ-39758979 in the Treatment of Adults with Persistent Asthma.

Johnson & Johnson - A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Investigate the Effect of JNJ-18054478 in Subjects with Asthma.

Map Pharmaceuticals - A Randomized, Double-Blind, Placebo Controlled, 3 Arm, Parallel Group, Phase 2 Study Investigating the Efficacy, Tolerability and Pharmacokinetics of MAP 0010 in Asthmatic Children and Adolescents Over 6 Weeks.

MedImmune - A Phase 2b, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous MEDI-528 in Adults with Uncontrolled Asthma.

MedImmune - A Phase 2b, Dose-ranging Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults with Uncontrolled Asthma.

MedImmune - A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Effect on Exercise Challenge Testing of Multiple Fixed Subcutaneous Doses of MEDI-528, a Humanized Anti-Interleukin-9 Monoclonal Antibody, in Adults with Stable Asthma and Exercise-Induced Bronchoconstriction.

Merck - A Multicenter, Double-Blind, Placebo Controlled, Randomized, Parallel-Group Study to Evaluate the Clinical Effect of Oral Montelukast Versus Placebo in Persistent Asthma Which is Also Active During Allergy Seasons in Pediatric Patients with Seasonal Aeroallergen Sensitivity.

Merck - A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, 8-Week Study to Evaluate the Efficacy and Safety of Chewable Montelukast When Initiated at the Start of the School Year in Pediatric Patients with Asthma.

Merck- A Multicenter, Double-Blind, Randomized, Parallel-Group Study Comparing the Clinical Effect of Three Oral Doses of MK-0476 and Placebo in Adult Patients with Stable, Moderate Asthma.

Merck- A Multicenter, Double-Blind, Randomized, Parallel-Group Study Comparing Montelukast With Placebo in Pediatric Patients Aged 6 to 24 Months with Asthma.

Merck- A Multicenter, Double-Blind, Randomized Study Investigating the Clinical Effect of Montelukast on Allergic Rhinitis in Patients with Seasonal Allergic Rhinitis and Chronic Asthma - Spring 2003 Study.

Merck- A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Effect of Montelukast Compared to Beclomethasone in Adult Asthmatics.

Merck - A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study to Evaluate the Clinical Effect of Oral Montelukast Versus Placebo During the Allergy Season in Patients with Seasonal Aeroallergen Sensitivity and Chronic Asthma Which is Also Active During Allergy Season.

Merck - A Six-week Evaluator-Blind, Randomized, Active-Controlled Evaluation of the Effects of Three Doses of Mometasone Furoate/Formoterol Fumarate (MF/F) Metered Dose Inhaler (MDI), Montelukast, and Beclomethasone Dipropionate (BDP HFA) on the HPA Axis in Asthmatic Children 5 to 11 Years of Age.

Merck - A 12-Week, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Mometasone Furoate Metered Dose Inhaler in the Treatment of Children Ages 5 to 11 Years With Persistent Asthma.

Merck - A 26-Week Randomized, Double-Blinded, Active Controlled Study Comparing the Safety of Mometasone Furoate/Formoterol Fumarate MDI Fixed Dose Combination Versus Mometasone Furoate MDI Monotherapy in Adolescents and Adults With Persistent Asthma.

Neurogen- A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Dose-Response Study Evaluating the Safety and Efficacy of Oral NGD 2000-1 Dibesylate Tablets in Patients with Mild to Moderate Asthma.

Novartis- A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center, Multiple Dose (7 days) Dose-Ranging Study, to Assess the Efficacy and Safety of 4 Doses of QAB149 (50, 100, 200 & 400 μg), Delivered via a Multiple Dose Inhaler, and 1 Dose of QAB149 (400 μg), Delivered via a Single Dose Inhaler, in Adult and Adolescent Patients (12-75 Years Old Inclusive) with Stable Persistent Asthma.

Novartis- An Epidemiologic Study of XOLAIR® (Omalizumab): Evaluating Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma (EXCELS).

Novartis- A 12-Week Randomized, Multicenter, Double-Blind, Placebo Controlled, Parallel Group Study in Children (aged 5-12, inclusive) with Persistent AsthmaEvaluating the Safety, Efficacy, and Pharmacokinetics of Foradil® (formoterol fumarate) 10 µg b.i.d. Delivered by the Multi-Dose Dry Powder Inhaler (MDDPI) Versus Placebo.

Novartis- A Phase III, 7-Month, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Trial With A 5-Month Blinded Extension Period To Assess The Efficacy, Safety, Tolerability, Steroid-Reduction, Phamakokinetics, And Phamacodynamics Of Subcutaneous Rhumab-E25 In Adolescents And Adults With Moderate To Severe Allergic Asthma Requiring Daily Treatment With Inhaled Corticosteroids.

Novartis- A 28 Week, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Omalizumab Administered Concomitantly with an Optimized Asthma Care Program in Patients with Allergic Asthma Already Demonstrating Inadequate Control Despite Currently Recommended Therapies.

Novartis- An Open-Label Extension to Provide Continuation of rhuMAb-E25 Treatment to Children with Allergic Asthma Who Participated in the One-Year Study.

Novartis- A Phase III, 7-Month, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multicenter Trial with a 5-Month Open-Label Extension Period to Assess Safety and Tolerability, Steroid-Reduction, Pharmacokinetics, and Pharmacodynamics of Subcutaneous rhuMAb-E25 in Children (6-12 Years) with Allergic Asthma Requiring Daily Treatment with Inhaled Corticosteroids.

Novartis- A Twelve-Month, Double-Blind, Between-Patient, Placebo-Controlled Trial Comparing the Safety, Tolerability, and Efficacy of 12 mcg and 24 mcg Daily Formoterol Dry Powder Capsules for Inhalation Delivered by a Single-Dose Inhaler (Aeroliser) in Children with Asthma in Need of Daily Treatment with Inhaled Bronchodilators and Corticosteroids.

Novartis- A Randomized, Multicenter, Placebo-Controlled Parallel Group Study of Four Months Duration Per Patient to Evaluate the Safety and Efficacy of Treatment with 24 µg b.i.d. and 12 µg b.i.d. Formoterol, Double-Blind, and 12 µg b.i.d. Formoterol with Additional On-Demand formoterol Doses, Open-Label, in Adolescent and Adult Patients with Persistent Asthma.

Novartis - A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Repeated-Dose Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Three Different Dosing Regimens of Inhaled Indacaterol Maleate in Patients with Persistent Asthma.

Novartis - A 26-Week Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients with Persistent Allergic Asthma.

Novartis - A Randomized, Multi-Center, Parallel Group, Double-Blind, Study to Assess the Safety of QMF Twisthaler (500/400mcg) and Mometasone Furoate Twisthaler (400mcg) in Adolescents and Adult Patients with Persistent Asthma.

Pfizer - An Assessment of the Pharmacokinetic and Pharmacodynamic Interaction Between Inhaled Insulin, a Short-Acting Bronchodilator and an Inhaled Corticosteroid in Non-Diabetic Subjects with Asthma.

Pfizer - A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Six-Week Study of the Efficacy and Safety of Tofimilast Dry Powder for Inhalation in Adults with Persistent Asthma.

Pfizer- Efficacy and Safety of Inhaled Human Insulin (Exubera®) Compared with Subcutaneous Human Insulin in the Therapy of Adult Subjects with Type 1 or Type 2 Diabetes Mellitus and Chronic Asthma: A One Year, Multicenter, Randomized, Outpatient, Open-Label, Parallel-Group Comparative Trial.

Pfizer- A Multicenter, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Zyrtec-D 12 HourTM (Cetirizine HCI/Pseudoephedrine HCI) Versus Placebo in Patient with Seasonal Allergic Rhinitis and Concomitant Mild to Moderate Asthma.

Pharmaxi Ltd. - A Phase III Multicenter Study to Demonstrate the Sensitivity and Specificity of Aridol (Mannitol) Challenge as Compared with Methacholine Challenge to Predict Bronchial Hyperresponsiveness as Manifested by a Positive Exercise Challenge in Subjects Presenting with Signs and Symptoms Suggestive of Asthmabut Without a Definitive Diagnosis.

Pozen- A Multicenter, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Zyrtec-D 12 Hour ® (Cetirzine HCI/Pseudoephedrine HCI) Versus Placebo in Patients with Seasonal Allergic Rhinitis and Concomitant Mild to Moderate Asthma.

Protein Design Lab- A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Daclizumab in Patients With Chronic, Persistent Asthma.

Protein Design Lab - A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Pilot Study of SB 240683 in Patents with symptomatic Steroid-Na®ve Asthma.

Rhone-Poulenc Rorer Pharmaceuticals, Inc.- A Phase II/III Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Efficacy, Safety And Dose Response Study Of Azmacort® (Triamcinolone Acetonide) HFA-134a Inhalation Aerosol 225 mcg, 450 mcg And 900 mcg Administered Once Daily For 12 Weeks In The Treatment Of Mild Persistent And Moderate Persistent Asthma In 800 Adolescents And Adults.

Rhone-Poulenc Rorer Pharmaceuticals, Inc.- A Placebo-Controlled, Double-Blind, Efficacy And Safety Study Of Azmacort Forte HFA-134a Oral Inhaler Compared To Azmacort® Oral Inhaler In The Treatment Of Asthma.

Rhone-Poulenc Rorer Pharmaceuticals, Inc.- A Six-Week Dose Response Study Of RPR 106541T 10 MCG BID, 50 MCG BID And 400 MCG BID Versus Beclomethasone Dipropionate 168 MCG BID Versus Placebo In Chronic Asthma.

Rhone-Poulenc Rorer Pharmaceuticals, Inc.- A Randomized, Placebo-Controlled, Parallel Group, Multiple-Dose Study of the Effects of Azmacort and Beclomethasone Dipropionate (BDP) in Pediatric Asthma Patients.

Rigel - A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Doses of Inhaled R940343 in Patients with Mild to Moderate Allergic Asthma.

Sanofi-Aventis - A Multicenter, Multi-National, Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy and Safety of Ciclesonide Metered-Dose Inhaler at 80 mcg BID or 40 mcg BID for 12 Weeks in Patients Aged 4 to <12 Years with Persistent Asthma

Sanofi-Aventis - A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy of Ciclesonide Metered-Dose Inhaler at a Daily Dose of 160 mcg Administered for 12 Weeks Either in a Once-Daily Regimen in the Morning (160 mcg qd AM) or in a Twice-Daily Regimen (80 mcg bid) in Adults and Adolescents with Mild to Moderate Persistent Asthma Treated Previously with Inhaled Corticosteroids.

Sanofi-Aventis - A Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy of Ciclesonide Metered-Dose Inhaler at a Daily Dose of 160 mcg Administered Either in a Once-Daily in the Morning Regimen (160 mcg qd AM) for 16 Weeks or in a 160 mcg qd AM Regimen for 12 Weeks Preceded by a Twice-Daily Regimen (80 mcg bid) for 4 Weeks, or in an 80 mcg bid Regimen for 16 Weeks, in Adults and Adolescents with Mild to Moderate Persistent Asthma Not Treated Steroids.

Sanofi-Aventis - A Placebo- and Active-Controlled, Parallel-Group, Dose-Finding Study of Formoterol Fumarate Given by Dry Powder Inhalation Using the Ultrahaler® in Adults and Adolescent Patients with Persistent Asthma.

Schering-Plough Research Institute - A 26-Week Placebo-Controlled Efficacy and Safety Study of Mometasone Furoate/Formoterol Fumarate Combination Formulation Compared with Mometasone Furoate and Formoterol Monotherapy in Subjects with Persistent Asthma Previously Treated with Low-Dose Inhaled Glucocorticosteroids.

Schering-Plough Research Institute - A 26-Week Placebo-Controlled Efficacy and Safety Study of Mometasone Furoate/Formoterol Fumarate Combination Formulation Compared with Mometasone Furoate and Formoterol Monotherapy in Subjects with Persistent Asthma Previously Treated with Medium-Dose Inhaled Glucocorticosteroids.

Schering-Plough Research Institute - A Comparative Study of the Efficacy and Tolerability of Maintenance Treatment of Patients with Mild/Moderate Persistent Asthmawith Asmanex Twisthaler 220 mcg QD PM Versus "Asmanex" Placebo QD PM.

Schering-Plough Research Institute - A 12-Week Efficacy and Safety Study of Two Doses of Mometasone Furoate / Formoterol Combination Formulation Compared with Mometasone Furoate Monotherapy, in Persistent Asthmatics Previously Treated with High-Dose Inhaled Glucocorticosteroids.

Schering-Plough Research Institute - A 52-Week Efficacy and Safety Non-Inferiority Study of Fluticasone Propionate/Salmeterol 250/50mcg BID Delivered by Dry Powder Inhaler (Diskus) Versus Mometasone Furoate/Formoterol Fumarate 200/10mcg BID Delivered by Pressurized Metered-Dose Inhaler in Persistent Asthmatics Previously Treated with Medium Doses of Inhaled Glucocorticosteroids.

Schering-Plough Research Institute - A Placebo-Controlled Study of the Effects of Pleconaril Nasal Spray on Common Cold Symptoms and Asthma Exacerbation Following Rhinovirus Exposure.

Schering-Plough- A Randomized, Double-Blind Study to Compare the Efficacy and Safety of Mometasone Furoate DPI and Fluticasone DPI in the Treatment of Asthma in Subjects Previously Maintained on Inhaled Corticosteroids.

Schering-Plough- A Study to Evaluate Subject Preference for Proventil® HFA-(Albuterol Sulfate Inhalation Aerosol) vs a Generic Albuterol Inhalation Aerosol: A Cross-over Study. (Asthma)

Schering-Plough- A Two-Year Study on the Effects of Mometasone Furoate Dry Powder Inhaler *MF-DPI) on Bone Density in Adult Asthmatics.

Schering-Plough- One Year Double Blind Study of the Effects of Mometasone Furoate Dry Powder Inhaler (MF DPI) vs. Placebo on Growth of Children with Asthma.

Schering-Plough- One-Year, Open-Label Safety Study of Mometasone Furoate Dry Powder Inhaler (MF DPI) and Beclomethasone Dipropionate (Vanceril® 84 mcg Double Strength) in Children with Asthma Previously Maintained on Inhaled Corticosteroids.

Schering-Plough- One-Year, Open-Label Safety Study of Mometasone Furoate HFA-227 Metered Dose Inhaler (MF MDI) and Beclomethasone Dipropionate (Vanceril® 84 mcg Double Strength) in Children with Asthma Previously Maintained on Inhaled Corticosteroids.

Schering-Plough- Placebo Controlled Dose Efficacy and Safety Study of Mometasone Furoate Dry Powder Inhaler (MF DPI) in the Treatment of Asthma in Children Previously Maintained on Beclomethasone Dipropionate (Vanceril® mcg Double Strength).

Schering-Plough- Placebo-Controlled Efficacy and Safety of Mometasone Furoate Dry Powder Compared to Beclomethasone Dipropionate (Vanceril®) in the Treatment of Asthma in Subjects Previously Maintained on Inhaled Corticosteroids.

Schering-Plough- Placebo-Controlled Efficacy and Safety Study of a Once Daily, PM Regimen, of Mometasone Furoate Dry Powder in Asthmatics Previously Maintained on Short-Acting Inhaled Beta-Agonists.

Schering-Plough- Placebo-Controlled Efficacy and Safety Study of Mometasone Furoate HFA-227 Metered Dose Inhaler in the Treatment of Asthma in Subjects Previously Maintained on Short-Acting Inhaled Beta-Agonists.

Schering-Plough- Placebo-Controlled, Dose-Ranging Study of Mometasone Furoate HFA-227 Metered Dose Inhaler Compared to Beclomethasone Dipropionate (Vanceril® 84 mcg Double Strength) in the Treatment of Asthma in Subjects Previously Maintained on Inhaled Corticosteroids.

Schering-Plough- Two-Year Study on the Effects of Mometasone Furoate Dry Powder Inhaler (MF DPI) on Bone Density in Young Adult Asthmatics.

Schering-Plough- Efficacy, Safety and Tolerance of Two Doses of SCH55770 vs. Placebo in Moderate and Severe Persistent Asthma.

Schering-Plough- Double-Blind Study of the Effects of One Year Treatment with Mometasone Furoate HFA-227 Metered Dose Inhaler (MF MDI) vs. Placebo on Growth of Children with Asthma.

Schering-Plough- A Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Mometasone Furoate DPI and Fluticasone DPI in the Treatment of Asthma in Subjects Previously Maintained on Inhaled Corticosteroids.

Schering-Plough- Placebo-Controlled Efficacy and Safety Study of Mometasone Furoate HFA-227 Metered Dose Inhaler Administered QD PM Versus BID in the Treatment of Asthma in Subjects Previously Maintained on Short-Acting Inhaled Beta-Agonists.

Schering-Plough- Placebo-Controlled, Efficacy and Safety Study with Long-Term Safety Evaluation of Mometasone Furoate HFA-227 Metered Dose Inhaler in Reducing Oral Prednisone Requirements in Subjects with Severe Asthma.

Schering-Plough- Placebo-Controlled Efficacy and Safety Study with Long Term Safety Evaluation of Mometasone Furoate Dry Powder in the Treatment of Asthma in Subjects Previously Maintained on Inhaled Beta-Agonists.

Schering-Plough - A Randomized, Evaluator-Blind, Crossover, Single Dose Study of the Bronchodilator Effect of Formoterol Fumarate in Combination with Mometasone Furoate Metered Dose Inhaler Delivered With and Without a Spacer Versus Placebo and Foradil Aerolizer in Children with Persistent Asthma.

Schering-Plough - An Open-Label, Multi Center, Patient Handling Study of Mometasone Furoate/Formoterol Fumarate MDI with an Integrated Dose Counter in Adolescents and Adult Subjects with Asthma or COPD.

Schering-Plough Research Institute - A 52-Week Efficacy and Safety Non-Inferiority Study of Fluticasone Propionate/Salmeterol 250/50mcg BID Delivered by Dry Powder Inhaler (Diskus) Versus Mometasone Furoate/Formoterol Fumarate 200/10mcg BID Delivered by Pressurized Metered-Dose Inhaler in Persistent Asthmatics Previously Treated with Medium Doses of Inhaled Glucocorticosteroids.

Schering-Plough- A Study of the Therapeutic Equivalency of MF DPI 100mcg and 200mcg Inhalers in Corticosteroid-Dependent Subjects with Moderate Asthma.

Schering-Plough - A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Grass (Phleum pratense) Sublingual Tablet (SCH 697243) in Subjects Between 5 and 65 Years of Age, With a History of Grass Pollen-Induced Rhinoconjuctivitis, With or Without Asthma.

Sepracor - A Safety, Efficacy, and Tolerability Study of Daily Dosing with Levalbuterol Tartrate HFA MDI and Placebo in Subjects Aged Birth to < 48 months with Asthma.

Sepracor - A Cumulative dose Safety and Tolerability Crossover Study of Arformoterol Tartrate Inhalation Solution and Levalbuterol Hydrochloride Inhalation Solution in Pediatric Subjects (Ages 2 to 11 years of age) with Asthma.

Sepracor- A Long Term Safety Study of Levalbuterol and Racemic Albuterol in Subjects Twelve Years of Age and Older with Asthma.

Sepracor- A Comparison of the Effect of Two Doses of Levalbuterol with Ventolin® on Pulmonary Function in Subjects with Mild-To-Moderate Asthma.

Sepracor- A Safety, Efficacy and Tolerability Study of Multiple Once-Daily Doses of (R,R)-formoterol tartrate Inhalation Solution in Subjects with Asthma. A Randomized, Placebo-controlled, Multi-center, Parallel-group Study.

Sepracor- An Efficacy, Safety and Tolerability Study of Daily Dosing with Levalbuterol Racemic Albuterol and Placebo in Pediatric Subjects 2-5 Years Old with Asthma.

Sepracor- (R)-Albuterol in the Reversal of Bronchoconstriction and in the Management of Asthma A Phase III Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study.

Sepracor- A Cumulative Dose Tolerability Study of Levalbuterol HFA and Racemic Albuterol HFA in Subjects Twelve Years of Age and Older with Asthma.

Sepracor- A Long Term Safety Study of Levalbuterol and Racemic Albuterol in Subjects Twelve Years of Age and Older with Asthma.

SmithKline Beecham- A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Oral Twice Daily Administration of SB 205312 in Patients with Mild to Moderate Asthma.

SmithKline Beecham- A Multicenter, Open, Long-Term Study of the Safety, Tolerability, and Efficacy of Oral SB 205312 in Patients with Bronchial Asthma.

SmithKline Beecham- A Repeat-Dose, Dose-Ranging, Placebo-Controlled Study of the Safety of SB210396 in Patients with Chronic Severe Asthma.

SmithKline Beecham- A Double-Blind, Double-Dummy, Placebo-Controlled, Randomized, Parallel Group Study to Examine the Effects of Oral SB205312 300mg BID in Patients with Asthma and Concomitant Seasonal Allergic Rhinitis - A Comparison to Patients Taking Inhaled Vanceril 168 mcg BID and as Required Nasal Rescue Medication.

SmithKline Beecham- A Repeat-Dose, Dose-Ranging, Placebo-Controlled Study of the Safety and Efficacy of SB 210396 in Patients with Chronic Severe Asthma.

Sonofi- A Multicenter Double-Blind Placebo-Controlled Dose Ranging Study To Assess And Compare The Activity Of An Oral Administration Of SR 27417a 2.5 10 And 30 mg Once A Day During 12 Weeks - In Moderate Asthmatic Patients.

Tap- A Study to Compare the Safety and Efficacy of Lansoprazole 30 mg BID Plus Usual Asthma Care Versus Placebo Plus Usual Asthma Care in Relieving Asthma Symptoms of Subjects with Asthma and Suspected Gastroesophageal Reflux (GERD).

Tap- Safety and Efficacy of AA-2414 (ABT-001) in Patients with Moderate Asthma.

Teva -Cumulative Dose Comparison of the Efficacy and Safety of Albuterol Spiromax and ProAir HFA in Adult Patients with Asthma.

Teva - A 12-Week Dose-ranging Study to Evaluate the Efficacy and Safety of Fp Spiromax® (Fluticasone Propionate Inhalation Powder) Administered Twice Daily compared with Placebo in Adolescent and Adult Subjects with Persistent Asthma Uncontrolled on Non-steroidal Therapy.

ViroPharma- A Double Blind, Placebo Controlled Exploratory Evaluation of Pleconaril (VP 63843) in the Treatment of Rhinovirus Upper Respiratory Tract Infections in Patients with Bronchial Asthma.

Viropharma- A Double-Blind, Placebo Controlled Exploratory Evaluation of Pleconaril (VP 63843) on the Treatment of Rhinovirus Upper Respiratory Tract Infections in Patients with Moderately Severe Bronchial Asthma.

Wyeth- Oral Albuterol Sulfate Dose-Response Study in Patients with Asthma.

Zeneca- A Multicenter, Double-Blind Comparison of Zafirlukast (ACCOLATE) with Placebo in Pediatric Subjects with Mild-to-Moderate Asthma including a Sub-protocol to Assess the Antagonism of Oral Zafirlukast (ACCOLATE) on Exercise-Induced Bronchoconstriction in Pediatric Subjects with Exercise-Induced Asthma at the End of Dosing Interval and During Long-Term Dosing Asthma.

Zeneca- A Multicenter, Double-blind Comparison of Zafirlukast (ACCOLATE®) with Placebo in Pediatric Subjects with Mild-to-Moderate Asthma.

Zeneca- A Multicenter, Double-Blind, Placebo Controlled Trial of Zafirlukast (ACCOLATE®) in Mild-to-Moderate Asthmatic Subjects Requiring First Chronic Therapy: 13 Weeks Efficacy and up to 52 Weeks Open-Label Safety Extension.

Zeneca- A Multicenter, Randomized, Double-blind, Parallel-group, 13-Week Trial Comparing Two Doses of Zafirlukast (ACCOLATE®) in Combination With Low-dose Inhaled Corticosteroids Versus High-dose inhaled Corticosteroids Alone in Subjects With Mild-to-Moderate Asthma.

Zeneca- A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, 15-week Trial of Zafirlukast (ACCOLATE®) Versus Low-dose Inhaled Corticosteroids After a 7-Day Course of Oral Corticosteroids in Subjects With Asthma.

Zeneca- A Multicenter, Randomized, Double-Blind Placebo Controlled Trial of Zafirlukast (ACCOLATE®) in Subjects with Mild to Moderate Asthma: 3 Weeks Efficacy and up to 52 Weeks Open-Label Safety Extension.

Zeneca- A Randomized, Double-blind, Placebo-Controlled, Dose Ranging, Parallel-group, Multicenter, Safety and Efficacy Trial of Zafirlukast (ACCOLATE®) in the Treatment of Pediatric Subjects with Mild-to-Moderate Asthma; Up to a 52 Week Open Label Safety Extension.

Zeneca- A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Multicenter, Safety and Efficacy Trial of Zafirlukast (ACCOLATE®) in the Treatment of Pediatric Subjects with Mild-to-Moderate Asthma.

Zeneca- A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial to Evaluate the Effect of Oral Zafirlukast (ACCOLATE®) on Growth in Prepubescent Children with Mild-to-moderate Asthma.

Zeneca- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial to Determine the Efficacy or Oral Zafirlukast (ACCOLATETM) When Administered According to Current Labeling Instructions or Simplified Dosing Instructions in Subjects with Asthma Receiving Inhaled B2-Agonist Alone or Inhaled B2-Agonist in Combination with Inhaled Corticosteroids (ICS).

Zeneca- A Multicenter, Randomized, Double-Blind, Parallel-Group Efficacy Trial Comparing Zafirlukast (Accolate) Plus Low-Dose Inhaled Corticosteroids Versus High-Dose Inhaled Corticosteroids Alone in Subjects with Mild-to-Moderate Asthma.

Bronchitis

Abbott Laboratories- A Comparative Study of the Safety, Efficacy and Effectiveness of Clarithromycin Extended-Release Tablets and Augmentin® Tablets for the Treatment of Subjects with Acute Exacerbation of Chronic Bronchitis.

Abbott Laboratories- A Comparative Study of the Efficacy and Safety of Clarithromycin Extended Release Tablets and Loracarbef Pulvules for the Treatment of Subjects with Secondary Bacterial Infections of Acute Bronchitis.

Abbott Laboratories- A Comparative Study of the Efficacy and Safety of Clarithromycin Extended Release Tablets and Clarithromycin Immediate Release Tablets for the Treatment of Subjects with Acute Exacerbation of Chronic Bronchitis.

Glaxo Wellcome- A Randomized, Double-Blind, Multicenter Comparison of the Efficacy and Safety of Grepafloxacin (RAXAR®) 400 mg or 600 mg Once Daily and Clarithromycin (BIAXIN®) 500 mg Twice Daily in the Treatment of Patients with Acute Bacterial Exacerbations of Chronic Bronchitis.

Tap Holdings- Comparative Safety and Efficacy of Cefditoren Pivoxil and Clarithromycin in the Treatment of Acute Bacterial Exacerbation of Chronic Bronchitis.

Chronic Obstructive Pulmonary Disease

Altana Pharma - Effect of Roflumilast on Exacerbation Rate in Patients with Chronic Obstructive Pulmonary Disease.

AstraZeneca- A 12-Month Double-Blind, Double-Dummy, Randomized, Parallel Group, Multicenter Efficacy and Safety Study of SYMBICORT® pMDI 2 x 160/4.5 μg bid and 2 x 80/4.5 μg bid Compared to Formoterol TBH 2 x 4.5 μg bid and Placebo in Patients with COPD.

AstraZeneca- A 6-Month Double-Blind, Double-Dummy, Randomized, Parallel Group, Multicenter Efficacy & Safety Study of SYMBICORT® pMDI 2 x 160/4.5 μg & 80/4.5 μg bid Compared to Formoterol TBH, Budesonide pMDI (& the Combination) & Placebo in COPD Patients.

Dey Laboratories - A 12-Week Double-Blind, Parallel-Group, Placebo- and Active-Controlled Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate Inhalation Solution 20 mcg/0.5 mL Delivered by OMRON MicroAir NE-U22V Nebulizer in the Treatment of Patients with Chronic Obstructive Pulmonary Disease.

Dey, L.P.- A 12-Week, Double-Blind, Parallel-Group, Placebo- and Active-Controlled Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate Inhalation Solution 20 mcg in the Treatment of Patients with Chronic Obstructive Pulmonary Disease.

Dey- A 12-week Double-Blind, Parallel-Group, Placebo- and Active-Controlled Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate Inhalation Solution 20 mcg in the Treatment of Patients with Chronic Obstructive Pulmonary Disease, Followed by a 40-Week Open-Label Safety Extension.

Forest Laboratories - A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy,Safety, and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and Placebo for 24-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)

Forest Laboratories - A Phase III, Long-Term, Randomized, Double-Blind, Extension Study of the Efficacy,Safety, and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)

GlaxoSmithKline - A Randomized, 24-Week, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety and Tolerability of Ariflo (15 mg BID) in Patients with Chronic Obstructive Pulmonary Disease (COPD).

MedImmune - A Phase 2a, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of MEDI-563 in Subjects with Moderate-to-severe Chronic Obstructive Pulmonary Disease and Sputum Eosinophilia.

Merck- A Double-Blind, Randomized, Placebo- and Active-Controlled, Multicenter, Parallel-Group, Dose-Ranging Study of L-753099 in Patients with COPD.

Novartis Pharmaceuticals - A 26-Week Treatment, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Adaptive, Seamless, Parallel-Group Study to Assess the Efficacy, Safety and Tolerability of Two Doses of Indacaterol (selected from 75, 150, 300 & 600 mcg o.d.) in Patients with Chronic Obstructive Pulmonary Disease Using Blinded Formoterol (12 mcg b.i.d.) and Open Label Titotropium (18 mcg o.d.) as Active

Novartis Pharmaceuticals - A 52-Week Treatment, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety and Tolerability of Indacaterol (200 & 400 mcg o.d.) in Patients with Chronic Obstructive Pulmonary Disease Using Open-Label Tiotropium (18 mcg o.d.) as an Active Control. - Protocol Post Text Supplement 1: Pharmacogenetic Study.

Novartis- A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center, Multiple Dose (7 days) Dose-Ranging Study, to Assess the Efficacy and Safety of 4 Doses of QAB149 (50, 100, 200 & 400 μg) Delivered Via a Multiple Dose Inhaler and 1 Dose of QAB149 (400 μg) Delivered Via a Single Dose Inhaler in Patients with Chronic Obstructive Pulmonary Disease (COPD).

Novartis - A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Two-Period Cross-Over Study to Assess the Effect of 50 mcg Inhaled NVA237 on Exercise Endurance in Patients with Moderate to Severe COPD.

Novartis - A 64-week treatment, multi-center, randomized, double-blind, parallel-group, active controlled study to evaluate the effect of QVA149 (110/50 µg o.d.) vs NVA237 (50 µg o.d.) and open-label tiotropium (18 µg o.d.) on COPD exacerbations in patients with severe to very severe chronic obstructive pulmonary disease (COPD).

Novartis - A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter, 3Period, 14-Day, Crossover Study to Determine the 24hr Lung Function Profile of Indacaterol (300mcg O.d) in Patients with Moderate-to-Severe COPD, Using Open-Label Salmeterol (50mcg BID) as Active Control.

Novartis - A 12-Week Treatment, Multi-Center, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Indacaterol (150mcg OD) in Patients with Chronic Obstructive Pulmonary Disease.

Novartis - A 12 Week Treatment, Multi-Center, Randomized, Parallel Group, Double Blind, Double Dummy Study to Assess the Superiority of Indacaterol (150mg OD) via a SDDPI in Patients with Moderate to Severe COPD, Using Salmeterol (50mcg BID) as an Active Comparator Delivered via Diskus Inhaler.

Novartis -A Randomized, Double-Blind, Controlled, Parallel-Group, 12-Week Treatment Study to Compare the Efficacy and Safety of the Combination of Indacaterol 150mcg Once Daily with Open Label Tiotropium 18mcg Once Daily Versus Open Label Tiotropium 18mcg Once Daily in Patients with Moderate-to-Serve COPD.

Novartis - A 12-Week Treatment, Multi-Center, Randomized, Parallel Group, Blinded, Double Dummy Study to Compare the Efficacy and Safety of Indacaterol (150mcg OD) Delivered Via A SSSPI with Tiotropium (18mcg OD) Delivered Via a Handihaler, in Patients with Moderate-to-Severe COPD.

Ono Pharma- A Four-Week, Double-Blind, Placebo-Controlled Exploratory Evaluation of FEV1.0 Changes and Safety of ONO-6126 in Patients with Chronic Obstructive Pulmonary Disease (COPD).

Pfizer - A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Six Week Study of the Efficacy and Safety of Tofimilast Dry Powder for Inhalation in Adults Diagnosed with Chronic Obstructive Pulmonary Disease.

Pfizer- Efficacy and Safety of Inhaled Human Insulin (Exubera®) Compared with Subcutaneous Human Insulin in the Therapy of Adult Subjects with Type 1 or Type 2 Diabetes Mellitus and Chronic Obstructive Pulmonary Disease: A One-Year, Multicenter, Randomized, Outpatient, Open-Label, Parallel-Group Comparative Trial.

Schering-Plough- Efficacy and Safety of Mometasone Furoate Dry Powder Inhaler in the Treatment of Patients With Chronic Obstructive Pulmonary Disease.

Sepracor Inc. - A Multicenter, Double-Blind, Double-Dummy, Randomized, Active-Controlled, Parallel Group Long-Term Safety Study of 15 mcg and 25 mcg Arformoterol Tartrate Inhalation Solution BID in the Treatment of Subjects with Chronic Obstructive Pulmonary Disease.

Sepracor- A Double-Blind, Double-Dummy, Randomized, Placebo- and Active-Controlled, Multicenter, Parallel-Group Study of (R,R), Formoterol in the Treatment of Subjects with Chronic Obstructive Pulmonary Disease.

Sepracor- A Multicenter, Open-Label, Randomized, Active-Controlled, Parallel Group Chronic Safety Study of (R,R) - Formoterol in the Treatment of Subjects with Chronic Obstructive Pulmonary Disease.

SmithKline Beecham- A Multicenter, Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Oral Ariflo (15 mg twice daily) in Patients with Chronic Obstructive Pulmonary Disease (COPD).

SmithKline Beecham- A Randomized, 24 week, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Tolerability of Ariflo (15 mg bid) in Patients with Chronic Obstructive Pulmonary Disease (COPD).

Viral Respiratory Infection

Viropharma- A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Efficacy, Virologic Activity, and Safety of Pleconaril (Oral Suspension) in the Treatment of Viral Respiratory Infection in Children 1 to 6 Years of Age.

Viropharma- A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Efficacy, Virologic Activity, and Safety of Pleconaril (Oral Suspension) in the Treatment of Viral Respiratory Infection in Children 7 to 12 Years of Age.

Idiopathic Pulmonary Fibrosis

Biogen Inc.- Efficacy of Avonex® in the Treatment of Idiopathic Pulmonary Fibrosis.

Sinusitis Research Experience

Bristol-Myers Squibb- An Open-Label, Multicenter, Non-Comparative Study of Oral BMS-284756 in the Treatment of Acute Bacterial Sinusitis in Patients Undergoing Sinus Aspirate.

Schering-Plough Research Institute - Efficacy and Safety of 200 mcg BID Mometasone Furoate Nasal Spray (MFNS) vs Placebo as Adjunctive Treatment to Antibiotics in Relief of Symptoms of Acute Bacterial Sinusitis.

Schering-Plough- Efficacy and Safety of 200 mcg QD or 200 mcg BID Mometasone Furoate Nasal Spray (MFNS) vs. Amoxicillin vs. Placebo as Primary Treatment of Subjects with Acute Rhinosinusitis.

Schering-Plough- Efficacy and Safety of 200 mcg or 400 mcg of Mometasone Furoate Nasal Spray or Placebo in the Treatment of Acute Episodes of Sinusitis.

Schering-Plough- Efficacy and Safety of 800mcg or 400mcg of Mometasone Furoate Nasal Spray or Placebo in the Treatment of Acute Episodes of Sinusitis.

Schering - Plough - A Study to Evaluate the Efficacy and Safety of 200 mcg or 400 mcg Mometasone Furoate Spray (MFNS) vs. Amoxicillin vs. Placebo as Primary Treatment of Symptoms of Acute Rhinosinusitis.

Tap Holdings- Comparative Safety and Efficacy of Cefditoren Pivoxil and Augmentin® (Amoxicillin/Clavulanate Potassium) in the Treatment of Patients with Acute Bacterial Sinusitis.

Dermatological Research Experience

Atopic Dermatitis

Altana Inc. - A Multicenter, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing ALTANA Inc's Tacrolimus Ointment 0.1% to PROTOPIC (Tacrolimus) Ointment 0.1% and Both Active Treatments to a Vehicle Control in the Treatment of Atopic Dermatitis.

Atlanta, Inc - A Multicenter, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing ALTANA Inc's Tacromlimus Ointment 0.03% to PROTOPIC (Tacrolimus) Ointment 0.03% and Both Active Treatments to a Vehicle Control in the Treatment of Atopic Dermatitis.

Novartis- A 13-day, randomized, multi-center, investigator-blinded, parallel group pharmacokinetic, safety, and local tolerability comparison of Elidel® cream 1% with tacrolimus ointment 0.1% in the treatment of adult subjects with moderate to severe atopic dermatitis, followed by 24-weeks of treatment with Elidel® cream 1% to evaluate long-term safety.

Novartis- A 26-week study with a 6-week, randomized, multi-center, investigator-blinded, exploratory comparative trial of the tolerability, safety and efficacy of Elidel® (pimecrolimus, SDZ ASM981) cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric subjects with moderate atopic dermatitis, followed by a 20-week open-label phase to study the safety of Elidel® (pimecrolimus, SDZ ASM981) cream 1%.

Novartis- A 3-Week Randomized, Multicenter, Double-Blind, Vehicle-Controlled, Parallel Group Study To Investigate The Efficacy And Safety Of 1% SDZ ASM 981 Cream In Subjects With Chronic Hand Dermatitis, Followed By A 23-Week Open Label Phase To Assess Long-Term Safety Of 1% SDZ ASM 981 Cream.

Novartis- A 6-month, parallel group, randomized, investigator-blind, placebo-controlled, multicenter proof of concept trial comparing the efficacy of E25 to that of placebo in the treatment of moderate to severe atopic dermatitis in subjects 6-16 years of age.

Schering-Plough- Efficacy and Safety of SCH 34117 in the Treatment of Atopic Dermatitis (AD).

Chronic Idiopathic Urticaria

Aventis- A Phase IIIa, Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study on the Efficacy and Safety of Fexofenadine HCI 180 mg Once Daily in Chronic Idiopathic Urticaria.

Hoechst Marion Roussel, Inc.- A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Study Comparing The Efficacy And Safety Of Four Dosage Strengths Of Fexofenadine HCI (20, 60, 120, & 240 mg Bid) In The Treatment Of

Chronic Idiopathic Urticaria.

Integrated Therapeutics - A Comparative Double-Blind, Double Dummy Study of Desloratadine (DL) 5 mg Once Daily, Cetirizine 10 mg Once Daily in Patients with Chronic Idiopathic Urticaria (CIU).

Pfizer- A Multicenter, Double Blind Comparative Study of the Efficacy and Safety of Zyrtec vs. Claritin and Placebo in the Treatment of Chronic Idiopathic Urticaria.

Schering-Plough- Efficacy and Safety in the Treatment of Chronic Idiopathic Urticaria (CIU) Subjects with SCH 34117.

Schering-Plough- An Open-Label Screening Protocol to Determine the Desloratadine Metabolic Phenotype of Atopic Pediatric Subjects and Pediatric Subjects with CIU (Ages > 2 to 12 Years).

Zeneca- Double-blind, Parallel Group Trial of Zafirlukast (ACCOLATE®) 20 mg BID in Combination with Cetrizine (ZYRTEC®) 10 mg at Bedtime Versus Cetirizine (ZYRTEC®) 10 mg at Bedtime for the Treatment of Subjects with Chronic Idiopathic Urticaria.

Psoriasis

Abgenix- A Two-Part, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Clinical Trial Of ABX-IL8 In Patients With Moderate To Severe Plaque Psoriasis.

Amgen, Inc. - An Open-Label Extension Study to Evaluate the Safety of Etanercept in Pediatric Subjects with Plaque Psoriasis. Amgen, Inc.

Amgen - A Multicenter, Open-Label, Prospective Study to Evaluate the Safety of Subjects with Psoriasis Treated with Etanercept.

Amgen - Placebo-Controlled Multicenter Study with Etanercept to Determine Safety and Efficacy in Pediatric Subjects with Plaque Psoriasis (PEDS).

Amgen- A Phase 3 Multicenter Study to Assess the Efficacy and Safety of Etanercept 50 mg Twice Weekly in Psoriasis.

Amgen- A Multicenter, Open Label Study to Observe the Effect of Etanercept on Joint and Skin Disease in Subjects with Psoriatic Arthritis.

Amgen- An Open-Label, Long-Term Extension Study to Assess the Safety of Etanercept in the Treatment of Psoriasis in Adult Subjects.

Amgen - A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Adding Methotrexate to Etanercept in Subjects with Moderate to Severe Plaque Psoriasis.

Amgen - A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-3.

Biogen Inc.- A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study of BG92273 in Subjects with Moderate to Severe Plaque Psoriasis.

Biogen- An Open-Label Study to Determine the Tolerability and Efficacy of Repeat Courses of LFA3TIP (LFA-3/IgG1 Fusion Protein) in Subjects with Chronic Plaque Psoriasis Who Have Previously Completed the C97-708

Boehringer Ingelheim - Safety, Tolerability, Efficacy, Pharmacokinetics, And Pharmacodynamics of Single Rising i.v. (Stage 1) and s.c. (Stage 2) Doses of BI 655066 in Male and Female Patients With Moderate to Severe Psoriasis (Randomised, Double-Blind, Placebo-Controlled Within Dose Groups).

Biogen- A Blinded, Multiple-Dose Study to Determine the Tolerability of Repeated Courses of LFA3TIP (LFA-3/IgG1 Fusion Protein) in Subjects with Moderate, Moderate to Severe, and Severe Plaque Psoriasis.

Centocor, Inc. - A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of CNTO 1275, a Fully Human Anti-IL-12 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Psoriatic Arthritis.

Centocor, Inc. - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Efficacy and Safety of CNTO 1275 in the Treatment of Subjects with Moderate to Severe Plaque-Type Psoriasis.

Centocor- A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel Study of Single and Multiple Dose Regimens with Subcutaneous CNTO 1275 (Human Monoclonal Antibody to IL-12) in Subjects with Moderate to Severe Psoriasis.

Centocor- A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Infliximab Induction Therapy Followed by Multiple Regimens on Maintenance Infliximab Therapy in Subjects with Plaque-Type Psoriasis.

Genentech- A Phase IIIb, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety of 1.0 mg/kg Subcutaneously Administered Efalizumab in Adults with Moderate to Severe Plaque Psoriasis Who are Candidates for Systemic Therapy.

Genentech- An Open-Label, Randomized, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneously Administered Anti-CD11a Used in Combination with Topical Psoriasis Therapies for Prolonged Maintenance Treatment.

Genentech- An Open-Label, Multicenter Study to Evaluate the Safety of 1.0 mg/kg Subcutaneously Administered Efalizumab in Adults with Plaque Psoriasis Previously Enrolled in Study ACD2600g.

GlaxoSmithKline- A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Three Dose Levels of Rosiglitazone Maleate in the Treatment of Chronic Plaque Psoriasis.

Immunex- Multicenter Dose Ranging Study of the Safety and Efficacy of Enbrel in Psoriasis.

Immunex- Double-Blind, Randomized, Placebo-Controlled Phase II Study of ENBREL® (Etanercept) in the Treatment of Psoriasis.

MedImmune- A Phase II Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Low Doses of MEDI-507, A Humanized Monoclonal Antibody That Binds to the CD2 Receptor, Administered by Subcutaneous Injection to Adults with Plaque Psoriasis

Schering-Plough - Randomized, Double-Blinded, Placebo-Controlled, Parallel-Design, Dose-Range Finding Study of Subcutaneous SCH 900222 in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis.

Serono- A Multicentre, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Subcutaneously Administered Onercept in the Treatment and Re-Treatment of Subjects with Moderate to Severe Plaque Psoriasis

Vertex- A Randomized, Blinded, Dose Ranging Safety, Tolerability and Preliminary Efficacy Study with VX-497 in Patients with Severe Chronic Plaque-Type Psoriasis.

Migraine Research Experience

AstraZeneca- A Multicenter, Double-Blind, Placebo-Controlled, Randomized Trial and an Open-Label Long-Term Tolerability Trial of Zolmitriptan (ZOMIGTM) for the Acute Treatment of Migraine Headaches in Adolescent Subjects.

Glaxo Wellcome- Patient Treatment Preference for and Satisfaction with Migraine Headache Therapy: IMITREX (sumatriptan succinate) Tablets Versus Current (non-triptan) therapy.

Glaxo Wellcome- A Randomized, Double-Blind, Double-Dummy, Active-Placebo Controlled, Parallel Group Evaluation of Oral Sumatriptan (50mg) Compared to Oral Napoxen Sodium (275 mg) on Migraine-Related Quality of Life.

Merck - A Worldwide, Open Label, Clinical Trial to Examine the Long Term Safety and Tolerability of Rizatriptan in Pediatric Migraineurs for the Treatment of Migraine With or Without Aura.

Merck - A Worldwide, Randomized, Double Blind, Placebo-Controlled, Parallel Group Clinical Trial to Evaluate the Safety and Efficacy of Rizatriptan for the Acute Treatment of Migraine in Children and Adolescents.

Pharmacia & Upjohn- A randomized, double-blind, placebo-controlled, single-dose, efficacy study in the treatment of acute migraine with or without aura.

Pozen- A Double-Blind, Placebo-Controlled, Study to Evaluate the Safety and Efficacy of MT100 Versus Over-Encapsulated Sumatriptan in Subjects with Acute Migraine Attacks.

Pozen- An Open-Label, Repeat Dose, Long-Term Safety Study of MT100 in Subjects with Acute Migraine Attacks.

Pozen- A Randomized, Double Blind, Placebo Controlled Evaluation of One or Two Doses of MT 100 in Subjects with Acute Migraine Attacks.

Zeneca- A Multicenter, Double-blind, Randomized Comparison of Zolmitriptan (311C90, ZOMIG®) and Sumatriptan in the Acute Treatment of Multiple MigraineHeadaches.

Miscellaneous Research Experience

Wyeth Consumer Healthcare - A Study to Evaluate the Efficacy and Safety of an Antitussive Agent Using Objective and Subjective Cough Assessments.

Berlex- A Multicenter, Double-Blind, Randomized, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy of a Monophasic Oral Contraceptive Preparation, Containing Drospirenone 3 mg and Ethinyl Estradiol 20 µg (as Beta-Cyclodextrin Clathrate), in the Treatment of Premenstrual Dysphoric Disorder (PMDD).

Glaxo Wellcome- A Multicenter, Open-Labeled Evaluation of the Safety of Zovirax (acyclovir) 5% Cream for the Treatment of Recurrent Herpes Labialis Infections in an Adolescent (12-17 years of age) Population.

Glaxo Wellcome- A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Evaluation of Ranitidine for the Reduction of Severity or Prevention of Meal-Induced Heartburn.

Merck- A Double-Blind, Placebo-Controlled, Parallel-Group, 12 Week Trial to Assess the Efficacy and Safety of MK-0663 in Patients with Chronic Low Back Pain.

Novartis- A 13 Week Multicenter Randomized Double-Blind Double Dummy Placebo-Controlled Parallel Group Trial Of 2 Doses Of COX189 (200 And 400 mg od) In Patients With Rheumatoid Arthritis Using Celecoxib (200 mg Bid) As A Comparator.

NPS Allelix Corp- An 18-Month Double-Blind, Placebo-Controlled, Phase III, Trial With A 12-Month Interim Analysis Of The Effect Of Recombinant Human Parathyroid Hormone (Alx1-11) On Fracture Incidence In Women With Postmenopausal Osteoporosis.

Reckitt Benckiser - Randomized, Double-Blind, Double Dummy, Placebo-Controlled Study of the Safety and Efficacy of Mucinex® (2400mg/d) and Immediate-Release Guaifenesin (800mg/d) in the Treatment of Symptoms of Acute Upper Respiratory Tract Infections For 7 Days.

Tap Holdings- Comparative Safety and Efficacy of Cefditoren Pivoxil and Penicillin VK in the Treatment of Patients with Streptococcal Pharyngitis.

Wyeth- Cold / Flu Efficacy and Safety Study.

Influenza

MedImmune- A Randomized, Double-Blind Trial To Assess The Safety And Relative Efficacy Of CAIV-T Against Inactivated Influenza Vaccine In Children 6-59 Months of Age.

Glaxo Wellcome- A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Investigate the Efficacy and Safety of Inhaled Zanamivir 10 mg Administered Once a Day for 28 Days in the Prevention of Symptomatic Influenza A and B Viral Infections in Community-Dwelling High Risk Subjects aged >12 years.

Hoffman LaRoche- A Double-Blind, Randomized, Stratified, Placebo-Controlled Study of Ro 64-0796 (also known as GS 4104) in Children with Influenza.

Hoffman LaRoche- A Double-Blind, Randomized, Placabo-Controlled Study of Ro 64-0796 (also known as GS 4104) used for the Prevention of Clinical Influenza Post Exposure in Families.

Roche- A Double-Blind, Randomized, Placebo Controlled Study Of RO 64-0796 (Also Known As GS4104) Used For The Prevention Of Clinical Influenza Post Exposure) In Families.

Otitis Media

Eli Lilly- Cefaclor Vs Cefuroxime Axetil In Difficult-To-Treat Acute Otitis Media.

Viropharma- A Double-Blind, Randomized, Placebo Controlled Evaluation of Pleconaril in the Prevention on Otitis Media in Children with a History of Otitis Media Following Picornavirus Respiratory Infection.

Generalized Anxiety Disorder

Biovail Laboratories- A Double-blind, Randomized, Placebo-Controlled, Parallel-Group, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of 60 mg Buspirone Hydrochloride Extended Release Compared to Placebo in Patients with Generalized Anxiety Disorder.

Biovail Laboratories- An Open-Label Study of the Safety, Tolerability, and Efficacy of up to 90 mg of Buspirone Hydrochloride Extended Release in Patients with Generalized Anxiety Disorder.

Diabetes

Bristol-Myers- A Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel Study of the Efficacy and Safety of Metformin Hydrochloride for the Treatment of Adolescents with Type 2 Diabetes Mellitus.

Pfizer- Efficacy and Safety of Inhaled Human Insulin (Exubera®) Compared with Subcutaneous Human Insulin in the Therapy of Adult Subjects with Type 1 or Type 2 Diabetes Mellitus and Chronic Asthma: A One Year, Multicenter, Randomized, Outpatient, Open-Label, Parallel-Group Comparative Trial.

Pfizer- Efficacy and Safety of Inhaled Human Insulin (Exubera®) Compared with Subcutaneous Human Insulin in the Therapy of Adult Subjects with Type 1 or Type 2 Diabetes Mellitusand Chronic Obstructive Pulmonary Disease: A One-Year, Multicenter, Randomized, Outpatient, Open-Label, Parallel-Group Comparative Trial.

Hypertension

Astra- Evaluation of the Antihypertensive Efficacy of Candesartan Cilexetil in Comparison to Losartan: A Multicenter, Double-Blind, Randomized, Parallel-Group, Forced-Titration Study.

Parexel- A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose Finding Study Of Lercanidipine Hydrochloride In Patients With Essential Hypertension.

Recordati- A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Finding Study of Lercanidipine Hydrochloride in Patients with Essential Hypertension.

Back To Top